var title_f10_6_10336="US of Bakers cyst";
var content_f10_6_10336=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F69614&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F69614&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ultrasound of Baker's cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 287px; height: 386px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Longitudinal US scan showing a large Baker's cyst and needle at upper right corner.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Juhani Koski, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_6_10336=[""].join("\n");
var outline_f10_6_10336=null;
var title_f10_6_10337="Anterior rhinoscopy with septal deviation";
var content_f10_6_10337=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F53443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F53443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anterior rhinoscopy with septal deviation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 376px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_6_10337=[""].join("\n");
var outline_f10_6_10337=null;
var title_f10_6_10338="Calcified cephalohematoma";
var content_f10_6_10338=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    5 week old with calcifying cephalohematoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rajvee Shah, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_6_10338=[""].join("\n");
var outline_f10_6_10338=null;
var title_f10_6_10339="Spondylolisthesis palpation";
var content_f10_6_10339=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lumbar palpation of spondylolytic spondylolisthesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 454px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bilateral pars defects at the L4 vertebra allow anterior displacement of the body and pedicles. The intact upper lumbar segments (L1-L3) move in unison with the displaced L4 body and pedicles, leaving the rest of the L4 neural arch behind, which will be palpated as the prominent spinous process (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Yochum TR, Rowe LJ. Yochum And Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy;2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_6_10339=[""].join("\n");
var outline_f10_6_10339=null;
var title_f10_6_10340="Pulmonary edema II PA";
var content_f10_6_10340=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75936&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75936&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute left ventricular failure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 363px; height: 302px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This plain frontal radiograph of the chest of a 30-year-old male demonstrates bilateral perihilar alveolar edema, giving a typical butterfly appearance, with bilateral interstitial edema and pulmonary venous redistribution to the upper lobes. The acute nature of this condition is manifest by the absence of pleural effusions or an enlarged cardiac silhouette.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_6_10340=[""].join("\n");
var outline_f10_6_10340=null;
var title_f10_6_10341="Adherence to tuberculosis treatment";
var content_f10_6_10341=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Adherence to tuberculosis treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/6/10341/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/6/10341/contributors\">",
"     Lee B Reichman, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/6/10341/contributors\">",
"     Alfred A Lardizabal, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/6/10341/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/6/10341/contributors\">",
"     C Fordham von Reyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/6/10341/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/6/10341/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/6/10341/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tuberculosis (TB) is nearly always curable if patients are treated with effective, uninterrupted antituberculous therapy. Adherence to treatment is critical for cure of individual patients, controlling spread of infection and minimizing the development of drug resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10341/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues related to treatment adherence will be reviewed here. The clinical approach to treatment of TB is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/21/19802?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHALLENGES OF ADHERENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incomplete adherence to treatment has been identified as the most serious problem in tuberculosis control [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10341/abstract/3\">",
"     3",
"    </a>",
"    ], and a major obstacle to the elimination of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10341/abstract/4\">",
"     4",
"    </a>",
"    ]. In one retrospective study including 184 patients with TB in New York City (nearly half of whom were nonadherent), the nonadherent patients took longer to convert to negative culture results (254 versus 64 days), were more likely to acquire drug resistance (relative risk 5.6), and required longer treatment regimens (560 versus 324 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10341/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment adherence can be particularly challenging in the setting of tuberculosis; the duration of treatment is long (usually six months or longer), combination therapy is required, and side effects may be unpleasant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Factors affecting adherence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful treatment among patients with TB may be influenced by several factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severity of symptoms",
"     </li>",
"     <li>",
"      Accessibility of medical care",
"     </li>",
"     <li>",
"      Number of medications and their side effects",
"     </li>",
"     <li>",
"      Dosing frequency",
"     </li>",
"     <li>",
"      Duration of treatment",
"     </li>",
"     <li>",
"      Personal and social characteristics of patients and providers",
"     </li>",
"     <li>",
"      Cultural beliefs of patients and providers",
"     </li>",
"     <li>",
"      Cultural sensitivity of providers",
"     </li>",
"     <li>",
"      Quality of training among providers",
"     </li>",
"     <li>",
"      Quantity and quality of information available about TB",
"     </li>",
"     <li>",
"      Extent of patient knowledge about TB",
"     </li>",
"     <li>",
"      Commitment of public health system to TB treatment",
"     </li>",
"     <li>",
"      Political, legislative, and economic factors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Health care providers must evaluate potential obstacles to treatment and facilitate educating and supporting patients to take the medications as prescribed. A poor caregiver-patient relationship is an important cause of nonadherence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk factors for nonadherence",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, up to half of patients do not follow medical recommendations or use medications as prescribed [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10341/abstract/6\">",
"     6",
"    </a>",
"    ]. No single group has been consistently identified to be at risk for nonadherence; the following patients may benefit from closer and monitoring:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who have previously failed to complete a regimen of antituberculous therapy (for treatment of active disease or latent infection) may be at increased risk of nonadherence. Patients who have had difficulty complying with other medical therapies may also be included in this group.",
"     </li>",
"     <li>",
"      Physically, emotionally, or mentally challenged patients may have difficulty remembering to take medications regularly.",
"     </li>",
"     <li>",
"      Patients actively abusing drugs, alcohol, or other addictive substances may have impaired cognition and distorted priorities. In addition, medications such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      may interfere with the euphoria associated with opiate abuse by accelerating its metabolism.",
"     </li>",
"     <li>",
"      Patients who come from distinct cultural or ethnic groups are at risk for nonadherence, particularly if the caregiver is not sensitive to these differences and is not prepared to address specific needs. Patients may not understand the need for therapy or may have cultural beliefs opposing therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one series of patients with tuberculosis in New York City, an increased rate of nonadherence was observed among African-Americans, injection drug users, homeless individuals, alcoholics, and HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10341/abstract/5\">",
"     5",
"    </a>",
"    ]. Multivariate analysis noted that the only consistent predictors of nonadherence were injection drug use and homelessness.",
"   </p>",
"   <p>",
"    Patients with none of the above \"risk factors\" who have difficulty with nonadherence include physicians and other health care workers [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10341/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     STRATEGIES TO IMPROVE ADHERENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Directly observed therapy (DOT) is the most important strategy for improvement in patient adherence [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10341/abstract/8\">",
"     8",
"    </a>",
"    ]. Other strategies include use of multidrug combination therapy if feasible, patient education, vouchers for transportation and other needs, and comprehensive case management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Directly observed therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Directly observed therapy (DOT) consists of observation by a health care provider or other responsible individual as a patient ingests antituberculous medications. In many programs, patients are observed taking their medications Monday through Friday and are given doses for the weekend.",
"   </p>",
"   <p>",
"    Regimens may be modified so that medication is given only two or three times per week (",
"    <a class=\"graphic graphic_table graphicRef50102 \" href=\"UTD.htm?23/25/23965\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef55978 graphicRef66493 \" href=\"UTD.htm?7/38/7790\">",
"     table 2A-B",
"    </a>",
"    ). A continuation phase regimen of once weekly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/51/15160?source=see_link\">",
"     rifapentine",
"    </a>",
"    (long acting rifamycin) may improve the feasibility and reduce the cost of DOT. However, once weekly treatment with DOT in the continuation phase should be used only for HIV-negative patients who have negative sputum smears after completing the initial phase of therapy and who do not have cavitation on initial radiograph [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10341/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    DOT programs require a significant commitment of resources but have been shown to be very effective [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10341/abstract/1\">",
"     1",
"    </a>",
"    ]. As an example, the community based DOT program in Baltimore illustrates the benefits derived from DOT [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10341/abstract/10\">",
"     10",
"    </a>",
"    ]. During the 1980s and early 1990s while TB incidence in the United States increased, Baltimore experienced a substantial decline by facilitating completion rates and bacteriologic evidence of cure.",
"   </p>",
"   <p>",
"    Another report from Texas compared 407 cases of TB (standard treatment) with 581 cases of TB (managed with DOT) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10341/abstract/11\">",
"     11",
"    </a>",
"    ]. Although the latter group had higher rates of tuberculosis, injection drug use, and homelessness, the following benefits of DOT observed:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A lower rate of primary drug resistance &mdash; 7 versus 13 percent",
"     </li>",
"     <li>",
"      A lower rate of acquired drug resistance &mdash; 2 versus 14 percent",
"     </li>",
"     <li>",
"      A lower relapse rate &mdash; 5 versus 21 percent",
"     </li>",
"     <li>",
"      Fewer relapses with resistant organisms &mdash; 1 versus 6 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the challenges of predicting patient adherence, the Centers for Disease Control and Prevention (CDC) and the American Thoracic Society (ATS) recommend consideration of DOT for all patients. Decisions regarding use of DOT may be based upon local rates of treatment completion and individual patient circumstances. Use of DOT is advisable for communities with treatment completion rates below 90 percent.Other groups that should receive DOT include patients with tuberculosis due to drug resistant organisms, cavitary disease or HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10341/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some studies have observed that DOT did not alter rates of treatment interruption, cure or other outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10341/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. A systematic review of the effectiveness of DOT from 1990 to 2000 analyzed 34 eligible studies from differing parts of the world; it found that while overall rates of treatment failure and relapse were low, considerable variability among studies existed in actual compliance and follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10341/abstract/15\">",
"     15",
"    </a>",
"    ]. Prospective data on drug compliance and follow-up are needed to demonstrate the true effectiveness of DOT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Multidrug combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of fixed dose combinations of antituberculous drugs simplifies therapy and reduces the possibility of missing a component of a multidrug regimen. These preparations also make monotherapy impossible, thereby preventing the development of acquired drug resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10341/abstract/16\">",
"     16",
"    </a>",
"    ]. Combination drugs that are available in the United States include Rifamate (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ) and Rifater (isoniazid, rifampin, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1914568\">",
"    <span class=\"h2\">",
"     Patient education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient education, combined with other interventions, is essential for ensuring adherence. The use of simple terms, limited information, and written and pictorial materials are all important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Incentives and enablers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incentives and enablers are used to encourage treatment adherence in facilities that provide TB services. Incentives are small \"rewards\" given to patients who adhere to the prescribed treatment regimen and maintain regular clinic visits. Enablers allow the patient to receive treatment more easily (eg, bus tickets or other means of transportation).",
"   </p>",
"   <p>",
"    Incentives (such as food supplements, food vouchers, cash, and clothing) are usually appreciated by patients and have been adopted by many state public health departments [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10341/abstract/17\">",
"     17",
"    </a>",
"    ]. Some data suggest that illicit drug users accept DOT at equal or higher rates than other patients if appropriate incentives and enablers are offered [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10341/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Comprehensive case management",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is advisable to provide teams of personnel who assume responsibility for continuity of care, case management, and follow-up. Case management involves case finding, problem identification, prioritizing, planning, patient advocacy, and reassessment.",
"   </p>",
"   <p>",
"    Appointment scheduling should be optimized for convenience. Telephone and postcard reminders are helpful. Home visits may also be useful for identifying and solve problems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Hospitalization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outpatient treatment with DOT may not be sufficient for adherence in some cases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10341/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In such circumstances, long-term hospitalization (voluntary or involuntary) may be necessary. In one series of 166 patients in Massachusetts, a dedicated medical-psychosocial inpatient unit facilitated completion of therapy in 97 percent of cases; hospitalization was required for the duration of therapy in 25 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10341/abstract/21\">",
"     21",
"    </a>",
"    ]. Among 67 nonadherent patients in California detained in prison rather than a hospital ward, a lower completion rate was observed (84 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10341/abstract/22\">",
"     22",
"    </a>",
"    ]. Involuntary confinement is a strategy of last resort [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10341/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1914577\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tuberculosis (TB) is nearly always curable if patients are treated with effective, uninterrupted antituberculous therapy. Adherence to treatment is critical for cure of individual patients, controlling spread of infection and minimizing the development of drug resistance. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Incomplete adherence to treatment has been identified as the most serious problem in tuberculosis control and a major obstacle to the elimination of the disease. Treatment adherence can be particularly challenging in the setting of tuberculosis; the duration of treatment is long (usually six months or longer), combination therapy is required, and side effects may be unpleasant. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Challenges of adherence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients at risk for nonadherence include those who have previously failed to complete a regimen of antituberculous therapy, those with physical or mental disability, those who are actively abusing addictive substances, and those from distinct cultural or ethnic groups who do not understand the need for therapy or hold cultural beliefs opposing therapy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk factors for nonadherence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Directly observed therapy (DOT) is the most important strategy for improvement in patient adherence. DOT consists of observation by a healthcare provider or other responsible individual as a patient ingests antituberculous medications. DOT programs require a significant commitment of resources but have been shown to be very effective in some studies. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Directly observed therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other strategies to improve adherence include use of multidrug combination therapy if feasible, patient education, vouchers for transportation and other needs, and comprehensive case management. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Strategies to improve adherence'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10341/abstract/1\">",
"      Chaulk CP, Kazandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis: Consensus Statement of the Public Health Tuberculosis Guidelines Panel. JAMA 1998; 279:943.",
"     </a>",
"    </li>",
"    <li>",
"     Chaulet, P. Treatment of tuberculosis: Case holding until cure. WHO/TB/83.141. Geneva, World Health Organization, 1983.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10341/abstract/3\">",
"      Addington WW. Patient compliance: the most serious remaining problem in the control of tuberculosis in the United States. Chest 1979; 76:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10341/abstract/4\">",
"      Mason JO. Opportunities for the elimination of tuberculosis. Am Rev Respir Dis 1986; 134:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10341/abstract/5\">",
"      Pablos-M&eacute;ndez A, Knirsch CA, Barr RG, et al. Nonadherence in tuberculosis treatment: predictors and consequences in New York City. Am J Med 1997; 102:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10341/abstract/6\">",
"      Sbarbaro JA. The patient-physician relationship: compliance revisited. Ann Allergy 1990; 64:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10341/abstract/7\">",
"      Miller B, Snider DE Jr. Physician noncompliance with tuberculosis preventive measures. Am Rev Respir Dis 1987; 135:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10341/abstract/8\">",
"      Volmink J, Garner P. Systematic review of randomised controlled trials of strategies to promote adherence to tuberculosis treatment. BMJ 1997; 315:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10341/abstract/9\">",
"      American Thoracic Society, CDC, Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep 2003; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10341/abstract/10\">",
"      Chaulk CP, Moore-Rice K, Rizzo R, Chaisson RE. Eleven years of community-based directly observed therapy for tuberculosis. JAMA 1995; 274:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10341/abstract/11\">",
"      Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10341/abstract/12\">",
"      Porco TC, Oh P, Flood JM. Antituberculosis drug resistance acquired during treatment: an analysis of cases reported in california, 1994-2006. Clin Infect Dis 2013; 56:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10341/abstract/13\">",
"      Zwarenstein M, Schoeman JH, Vundule C, et al. Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis. Lancet 1998; 352:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10341/abstract/14\">",
"      Walley JD, Khan MA, Newell JN, Khan MH. Effectiveness of the direct observation component of DOTS for tuberculosis: a randomised controlled trial in Pakistan. Lancet 2001; 357:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10341/abstract/15\">",
"      Hill AR, Manikal VM, Riska PF. Effectiveness of directly observed therapy (DOT) for tuberculosis: a review of multinational experience reported in 1990-2000. Medicine (Baltimore) 2002; 81:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10341/abstract/16\">",
"      Moulding T, Dutt AK, Reichman LB. Fixed-dose combinations of antituberculous medications to prevent drug resistance. Ann Intern Med 1995; 122:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10341/abstract/17\">",
"      Buchanan RJ. Compliance with tuberculosis drug regimens: incentives and enablers offered by public health departments. Am J Public Health 1997; 87:2014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10341/abstract/18\">",
"      Salomon N, Perlman DC, Rubenstein A, et al. Implementation of universal directly observed therapy at a New York City hospital and evaluation of an out-patient directly observed therapy program. Int J Tuberc Lung Dis 1997; 1:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10341/abstract/19\">",
"      Burman WJ, Cohn DL, Rietmeijer CA, et al. Noncompliance with directly observed therapy for tuberculosis. Epidemiology and effect on the outcome of treatment. Chest 1997; 111:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10341/abstract/20\">",
"      Gasner MR, Maw KL, Feldman GE, et al. The use of legal action in New York City to ensure treatment of tuberculosis. N Engl J Med 1999; 340:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10341/abstract/21\">",
"      Singleton L, Turner M, Haskal R, et al. Long-term hospitalization for tuberculosis control. Experience with a medical-psychosocial inpatient unit. JAMA 1997; 278:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10341/abstract/22\">",
"      Oscherwitz T, Tulsky JP, Roger S, et al. Detention of persistently nonadherent patients with tuberculosis. JAMA 1997; 278:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10341/abstract/23\">",
"      Lerner BH. Catching patients: tuberculosis and detention in the 1990s. Chest 1999; 115:236.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8019 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.69.132.100-0D12DA5E94-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_6_10341=[""].join("\n");
var outline_f10_6_10341=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1914577\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHALLENGES OF ADHERENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Factors affecting adherence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk factors for nonadherence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      STRATEGIES TO IMPROVE ADHERENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Directly observed therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Multidrug combination therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1914568\">",
"      Patient education",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Incentives and enablers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Comprehensive case management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Hospitalization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1914577\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8019\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8019|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/25/23965\" title=\"table 1\">",
"      Drug regimens for tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/12/25804\" title=\"table 2A\">",
"      First-line TB drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/8/13453\" title=\"table 2B\">",
"      Second line TB drugs for adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/21/19802?source=related_link\">",
"      Treatment of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=related_link\">",
"      Treatment of pulmonary tuberculosis in the HIV-infected patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_6_10342="Dexrazoxane: Pediatric drug information";
var content_f10_6_10342=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dexrazoxane: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?29/28/30150?source=see_link\">",
"    see \"Dexrazoxane: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?8/39/8820?source=see_link\">",
"    see \"Dexrazoxane: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F158533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Totect&reg;;",
"     </li>",
"     <li>",
"      Zinecard&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F158534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Zinecard&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1046979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Cardioprotective Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Chelating Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1046972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/28/30150?source=see_link\">",
"      see \"Dexrazoxane: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents:",
"     <b>",
"      Prevention of anthracycline cardiomyopathy associated with acute lymphoblastic leukemia (ALL):",
"     </b>",
"     I.V.: A 10:1 dose ratio of dexrazoxane:doxorubicin (example: 300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     dexrazoxane: 30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     doxorubicin) (Lipshultz, 2010; Moghrabi, 2007; Silverman, 2010).",
"     <b>",
"      Note:",
"     </b>",
"     Cardiac monitoring should continue during dexrazoxane therapy; anthracycline/dexrazoxane should be discontinued in patients who develop a decline in LVEF or clinical CHF.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Prevention of doxorubicin cardiomyopathy:",
"     </b>",
"     I.V.: A 10:1 ratio of dexrazoxane:doxorubicin (dexrazoxane 500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     :doxorubicin 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ).",
"     <b>",
"      Note:",
"     </b>",
"     Cardiac monitoring should continue during dexrazoxane therapy; doxorubicin/dexrazoxane should be discontinued in patients who develop a decline in LVEF or clinical CHF.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Treatment of extravasation:",
"     </b>",
"     I.V.: 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1 and 2 (maximum dose: 2000 mg), followed by 500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 3 (maximum dose: 1000 mg); begin treatment as soon as possible, within 6 hours of extravasation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Renal function may be estimated using the Cockcroft-Gault formula.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate-to-severe (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;40 mL/minute):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prevention of cardiomyopathy: Reduce dose by 50%, using a 5:1 dexrazoxane:doxorubicin ratio (Example: 250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     dexrazoxane: 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     doxorubicin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Anthracycline-induced extravasation: Reduce dose by 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prevention of cardiomyopathy: Since doxorubicin dosage is reduced in hyperbilirubinemia, a proportional reduction in dexrazoxane dosage is recommended (maintain a 10:1 ratio of dexrazoxane:doxorubicin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anthracycline-induced extravasation: Use has not been evaluated in patients with hepatic dysfunction",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F158514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 250 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Totect&reg;: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zinecard&reg;: 250 mg, 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F158500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1046983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prevention of doxorubicin cardiomyopathy: Administer doxorubicin within 30 minutes after beginning the infusion with dexrazoxane.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Zinecard&reg;: Reconstitute vial with SWI to a concentration of dexrazoxane 10 mg/mL. Prior to infusion, further dilute reconstituted dexrazoxane solution in lactated Ringer&rsquo;s injection to a final concentration of 1.3-3 mg/mL. Administer by rapid drip infusion; do",
"     <b>",
"      not",
"     </b>",
"     administer by I.V. push.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dexrazoxane generic formulation (Bedford Laboratories, Mylan, Inc): Reconstitute with the supplied diluent (0.167 Molar sodium lactate injection) to a final concentration of 10 mg/mL. Prior to infusion, further dilute reconstituted dexrazoxane solution with D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS to a final concentration of 1.3-5 mg/mL. Administer by slow I.V push or rapid drip infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treatment of anthracycline extravasation:  Reconstitute 500 mg vial with 50 mL of the supplied diluent (0.167 Molar sodium lactate injection) to a final concentration of 10 mg/mL. Prior to infusion, further dilute reconstituted dexrazoxane solution in NS 1000 mL. Administer I.V. over 1-2 hours; begin infusion as soon as possible, within 6 hours of extravasation. Infusion solution should be at room temperature prior to administration. Infuse in a large vein in an area remote from the extravasation. If extravasation is also being managed with cooling, withhold cooling beginning 15 minutes before dexrazoxane infusion; continue withholding cooling until 15 minutes after infusion is completed. Day 2 and 3 doses should be administered at approximately the same time (&plusmn; 3 hours) as the dose on day 1. For I.V. administration; not for local infiltration into extravasation.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F158561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS (Totect&reg;, generic formulations reconstituted with 0.167 M sodium lactate), D",
"     <sub>",
"      5",
"     </sub>",
"     W (generic formulations reconstituted with 0.167 M sodium lactate), LR (Zinecard&reg;)",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1046975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Preparation and storage are product specific; refer to individual product labeling for further details. Use appropriate precautions for handling and disposal. Discard unused solutions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Totect&reg;: Store intact vials at room temperature of 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from light. When reconstituted with the supplied diluent to a final concentration of 10 mg/mL, the reconstituted solution is stable for 2 hours. Solutions for infusion are stable for 4 hours when stored &lt;25&deg;C (&lt;77&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zinecard&reg;: Store intact vials at room temperature of 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). When reconstituted with SWI, the reconstituted solution is stable for 30 minutes at room temperature or 3 hours under refrigeration. Solutions for infusion are stable for 1 hour when stored at room temperature or 4 hours under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexrazoxane generic formulation (Bedford Laboratories; Mylan, Inc): Store intact vials at room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Reconstituted solutions and solutions diluted for infusion are stable for 6 hours when stored at room temperature or under refrigeration 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Additional stability information: When studied as a 24-hour continuous infusion for the prevention of cardiomyopathy, solutions prepared with sodium lactate diluent and diluted to a final concentration of 0.1 or 0.5 mg/mL in D",
"     <sub>",
"      5",
"     </sub>",
"     W were found to retain &ge;90% of their initial concentration when stored at room temperature (ambient light conditions) for &le;24 hours (Tetef, 2001).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1046982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zinecard&reg;: Reduction of anthracycline-induced (ie, doxorubicin-induced) cardiotoxicity in women with metastatic breast cancer (FDA approved in adults). Not  recommended for use with initial anthracycline therapy; most dexrazoxane studies have been done in women with metastatic breast cancer who had received a cumulative doxorubicin dose of 300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     .  Has also been used for prevention of doxorubicin cardiomyopathy associated with treatment of acute lymphoblastic leukemia (ALL).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Totect&reg;: Treatment of anthracycline extravasation (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F158563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Zinecard&reg; may be confused with Gemzar&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F158560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Most adverse reactions are thought to be attributed to chemotherapy, except for increased myelosuppression, pain at injection site, and phlebitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Prevention of doxorubicin cardiomyopathy",
"     </b>",
"     (reactions listed are those which were greater in the dexrazoxane arm in a comparison of chemotherapy plus dexrazoxane vs chemotherapy alone):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Fatigue/malaise, fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia, streaking/erythema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Serum amylase increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Granulocytopenia, leukopenia, myelosuppression, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Extravasation, injection site pain, phlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Neurotoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection, sepsis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Anthracycline extravasation:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Depression, dizziness, fatigue, fever, headache, insomnia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Alopecia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypercalcemia, hyponatremia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, constipation, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Hematologic: Anemia, leukopenia, neutropenia, neutropenic fever, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Hepatic:  Alkaline phosphatase increased, ALT increased, AST increased, bilirubin increased, LDH increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Local: Injection site pain/discomfort, phlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Renal: Creatinine increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea, pneumonia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Infection",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1046986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dexrazoxane or any component; Zinecard&reg; should only be used with chemotherapy regimens containing an anthracycline",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1046971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Do not give doxorubicin prior to dexrazoxane administration.",
"     </b>",
"     Doxorubicin should be given within 30 minutes after the beginning of a dexrazoxane infusion when used for the prevention of cardiomyopathy. For I.V. administration;",
"     <b>",
"      not",
"     </b>",
"     for local infiltration into extravasation site. Do not use dimethylsulfoxide (DMSO) in patients receiving dexrazoxane for anthracycline-induced extravasation; may diminish dexrazoxane efficacy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in patients for hepatic impairment; adjust dosage; a proportional dose reduction in dexrazoxane is recommended to maintain the dosage ratio of 10:1. Use with caution in patients with renal impairment; dosage adjustment required for Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;40 mL/minute.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1046970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal. Based on limited experience, the possibility of dexrazoxane interference with antineoplastic efficacy may exist; use Zinecard&reg; only in those patients who have received a cumulative doxorubicin dose of 300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     and are continuing with doxorubicin therapy. Does not eliminate the potential for anthracycline-induced cardiac toxicity; carefully monitor cardiac function. May cause mild myelosuppression activity (leukopenia, neutropenia, and thrombocytopenia); may be additive with concurrently administered chemotherapeutic agents. Secondary malignant neoplasms (SMN) have been reported with dexrazoxane and razoxane use [racemic mixture of which dexrazoxane is the S(+) enantiomer]; a  multicenter review of pediatric trials reported the incidence of SMN to be very rare; a single case was reported out of 533 pediatric patients evaluated throughout 5-year follow-up (Vrooman, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6219749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dimethyl Sulfoxide: May diminish the therapeutic effect of Dexrazoxane.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F158510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F158523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies using doses less than the equivalent human dose (based on BSA).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1046978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential (frequent); liver function; serum creatinine; cardiac function (for adults: repeat monitoring at 400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     , 500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     , and with every 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     of doxorubicin thereafter); monitor site of extravasation",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1046969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dexrazoxane is a cyclic derivative of ethylenediaminetetraacetic acid (EDTA) that rapidly penetrates the myocardial cell membrane. It binds intracellular iron and prevents generation of oxygen free radicals by anthracyclines. Dexrazoxane is hydrolyzed intracellularly to an open-ring chelating agent which is responsible for chelating heavy metals and preventing formation of superhydroxide free radicals believed to be responsible for anthracycline-induced cardiomyopathy. Dexrazoxane may also have antitumor activity and have synergistic activity with certain cytotoxic agents. In the management of anthracycline-induced extravasation, dexrazoxane may act by reversibly inhibiting topoisomerase II, protecting tissue from anthracycline cytotoxicity, thereby decreasing tissue damage.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1046985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Distributes to heart, liver, and kidneys",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: 0.96 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 22-25 L/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Insignificant",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hydrolyzed by dihydropyrimidine aminohydrolase and dihydrocrotase",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Biphasic: Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Distribution half-life: 8-21 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elimination half-life: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 40% to 60% of dose excreted renally within 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F6137603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/39/8820?source=see_link\">",
"      see \"Dexrazoxane: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Women of childbearing potential should be advised that Totect&reg; may cause fetal harm; consult prescriber for appropriate contraceptive measures. Notify physician of bleeding or bruising problems.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Brier ME, Gaylor SK, McGovren JP, et al, \"Pharmacokinetics of Dexrazoxane in Subjects With Impaired Kidney Function,\"",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2011, 51(5):731-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/6/10342/abstract-text/20484616/pubmed\" id=\"20484616\" target=\"_blank\">",
"        20484616",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hensley ML, Hagerty KL, Kewalramani T, et al, \"American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiation Therapy Protectants,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(1):127-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/6/10342/abstract-text/19018081/pubmed\" id=\"19018081\" target=\"_blank\">",
"        19018081",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holcenberg JS, Tutsch KD, Earhart RH, et al, \"Phase I Study of ICRF-187 in Pediatric Cancer Patients and Comparison of Its Pharmacokinetics in Children and Adults,\"",
"      <i>",
"       Cancer Treat Rep",
"      </i>",
"      , 1986, 70(6):703-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/6/10342/abstract-text/3089595/pubmed\" id=\"3089595\" target=\"_blank\">",
"        3089595",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lipshultz SE, Rifai N, Dalton VM, et al, \"The Effect of Dexrazoxane on Myocardial Injury in Doxorubicin-Treated Children With Acute Lymphoblastic Leukemia,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 351(2):145-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/6/10342/abstract-text/15247354/pubmed\" id=\"15247354\" target=\"_blank\">",
"        15247354",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lipshultz SE, Scully RE, Lipsitz SR, et al, \"Assessment of Dexrazoxane as a Cardioprotectant in Doxorubicin-Treated Children With High-Risk Acute Lymphoblastic Leukaemia: Long-Term Follow-Up of a Prospective, Randomised, Multicentre Trial,\"",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2010, 11(10):950-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/6/10342/abstract-text/20850381/pubmed\" id=\"20850381\" target=\"_blank\">",
"        20850381",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moghrabi A, Levy DE, Asselin B, et al, \"Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for Children With Acute Lymphoblastic Leukemia,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2007, 109(3):896-904.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/6/10342/abstract-text/17003366/pubmed\" id=\"17003366\" target=\"_blank\">",
"        17003366",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sehested M, Holm B, and Jensen PB, &ldquo;Dexrazoxane for Protection Against Cardiotoxic Effects of Anthracyclines,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1996, 14:2884.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/6/10342/abstract-text/9626452 /pubmed\" id=\"9626452 \" target=\"_blank\">",
"        9626452",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silverman LB, Stevenson KE, O'Brien JE, et al, \"Long-Term Results of Dana-Farber Cancer Institute ALL Consortium Protocols for Children With Newly Diagnosed Acute Lymphoblastic Leukemia (1985-2000),\"",
"      <i>",
"       Leukemia",
"      </i>",
"      , 2010, 24(2):320-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/6/10342/abstract-text/20016537/pubmed\" id=\"20016537\" target=\"_blank\">",
"        20016537",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Swain SM, Whaley FS, Gerber MC, et al, &ldquo;Cardioprotection With Dexrazoxane for Doxorubicin-Containing Therapy in Advanced Breast Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1997, 15:1318-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/6/10342/abstract-text/9193323/pubmed\" id=\"9193323\" target=\"_blank\">",
"        9193323",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Swain SM, Whaley FS, Gerber MC, et al, &ldquo;Delayed Administration of Dexrazoxane Provides Cardioprotection for Patients With Advanced Breast Cancer Treated With Doxorubicin-Containing Therapy,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1997, 15:1333-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/6/10342/abstract-text/9193324 /pubmed\" id=\"9193324 \" target=\"_blank\">",
"        9193324",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tetef ML, Synold TW, Chow W, et al, \"Phase I Trial of 96-Hour Continuous Infusion of Dexrazoxane in Patients With Advanced Malignancies,\"",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2001, 7(6):1569-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/6/10342/abstract-text/11410492/pubmed\" id=\"11410492\" target=\"_blank\">",
"        11410492",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vrooman LM, Neuberg DS, Stevenson KE, et al, \"The Low Incidence of Secondary Acute Myelogenous Leukaemia in Children and Adolescents Treated With Dexrazoxane for Acute Lymphoblastic Leukaemia: A Report From the Dana-Farber Cancer Institute ALL Consortium,\"",
"      <i>",
"       Eur J Cancer",
"      </i>",
"      , 2011, 47(9):1373-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/6/10342/abstract-text/21514146/pubmed\" id=\"21514146\" target=\"_blank\">",
"        21514146",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wexler LH, Andrich MP, Venzon D, et al, &ldquo;Randomized Trial of the Cardioprotective Agent ICRF-187 in Pediatric Sarcoma Patients Treated With Doxorubicin,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1996, 14:362-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/6/10342/abstract-text/8636745/pubmed\" id=\"8636745\" target=\"_blank\">",
"        8636745",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13216 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-89.32.226.102-21F53BA666-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_6_10342=[""].join("\n");
var outline_f10_6_10342=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158533\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158534\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046979\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046972\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158514\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158500\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046983\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158561\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046975\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046982\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158563\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158560\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046986\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046971\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046970\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299160\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6219749\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158510\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158523\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046978\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046969\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046985\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6137603\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13216\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13216|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/28/30150?source=related_link\">",
"      Dexrazoxane: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/39/8820?source=related_link\">",
"      Dexrazoxane: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_6_10343="Perphenazine: Pediatric drug information";
var content_f10_6_10343=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Perphenazine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?18/49/19223?source=see_link\">",
"    see \"Perphenazine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?11/50/12069?source=see_link\">",
"    see \"Perphenazine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F7290569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F208621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Perphenazine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1030644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiemetic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antipsychotic Agent, Typical, Phenothiazine",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Phenothiazine Derivative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1030676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/49/19223?source=see_link\">",
"      see \"Perphenazine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Dosage should be individualized; use lowest effective dose and shortest effective duration; periodically reassess the need for continued treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"     <b>",
"      Note:",
"     </b>",
"     Safety and efficacy have not been established in children &lt;12 years of age; use in this age group is not recommended by manufacturer. Some centers use the following doses:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Schizophrenia/psychoses:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &lt;1 year: Dosage not established",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1-6 years: 4-6 mg/day in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     6-12 years: 6 mg/day in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;12 years: 4-16 mg 2-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Postoperative vomiting: Dosage not established; use not recommended. Previous studies used an I.V. dose of 70 mcg/kg (maximum: 5 mg/dose) in children 2-12 years of age to decrease postoperative vomiting; perphenazine was shown to be more effective than placebo (Splinter, 1997), more effective than dexamethasone (Splinter, 1997a), and similar in efficacy to ondansetron (Splinter, 1998). However, I.V. granisetron was shown to be more effective than I.V. perphenazine (Fujii, 1999). Only one study has assessed oral perphenazine; doses of 70 mcg/kg were administered 1 hour prior to surgery to 100 children, 4-10 years of age, to reduce postoperative vomiting; oral granisetron was more effective than oral perphenazine (Fujii, 1999a).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Schizophrenia/psychoses: 4-16 mg 2-4 times/day; maximum: 64 mg/day (exceptions occur; indication specific)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nausea/vomiting: 8-16 mg/day in divided doses; maximum: 24 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Specific guidelines are not available; consider dosage reduction in patients with liver disease",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F208600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 2 mg, 4 mg, 8 mg, 16 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F208585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5948059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals; do not administer within 2 hours of antacids",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1030664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at controlled room temperature at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); dispense in tight, light-resistant container",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1030645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of schizophrenia (FDA approved in ages &ge;12 years and adults); severe nausea and vomiting (FDA approved in adults); other psychotic disorders (eg, schizoaffective disorder), psychotic depression",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F208662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Trilafon may be confused with Tri-Levlen&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F208660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, cardiac arrest, ECG changes, hyper-/hypotension, orthostatic hypotension, pallor, peripheral edema, sudden death, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Bizarre dreams, catatonic-like states, cerebral edema, dizziness, drowsiness, extrapyramidal symptoms (pseudoparkinsonism, akathisia, dystonias, tardive dyskinesia), faintness, headache, hyperactivity, hyperpyrexia, impairment of temperature regulation, insomnia, lethargy, neuroleptic malignant syndrome (NMS), nocturnal confusion, paradoxical excitement, paranoid reactions, restlessness, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Discoloration of skin (blue-gray), photosensitivity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, breast enlargement, hyper-/hypoglycemia, galactorrhea, lactation, libido changes, gynecomastia, menstrual irregularity, parotid swelling (rare), SIADH",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Adynamic ileus, anorexia, appetite increased, constipation, diarrhea, fecal impaction, obstipation, nausea, salivation, vomiting, weight gain, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Bladder paralysis, ejaculatory disturbances, incontinence, polyuria, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, eosinophilia, hemolytic anemia, leukopenia, pancytopenia, thrombocytopenic purpura",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatotoxicity, jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, cornea and lens changes, epithelial keratopathies, glaucoma, mydriasis, myosis, photophobia, pigmentary retinopathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Glycosuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Nasal congestion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, diaphoresis, systemic lupus erythematosus-like syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1030649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to perphenazine or any component; cross-sensitivity with other phenothiazines may exist; severe CNS depression; subcortical brain damage; bone marrow suppression; blood dyscrasias; coma",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F5734285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hemodynamic instability; may cause hypotension; predisposition to seizures; cardiac, hepatic, renal, or respiratory disease; psychic depression. May cause sedation, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving); use with caution in disorders where CNS depression is a feature. Use with caution in Parkinson's disease. Esophageal dysmotility and aspiration have been associated with antipsychotic use; use with caution in patients at risk of pneumonia. Use with caution in breast cancer or other prolactin-dependent tumors; may elevate prolactin levels. May alter temperature regulation; use with caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects. May mask toxicity of other drugs due to antiemetic effects. May alter cardiac conduction; life-threatening arrhythmias have occurred with therapeutic doses of phenothiazines. May cause orthostatic hypotension; use with caution in patients at risk of this effect or those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, or other medications which may predispose). May cause photosensitization; avoid prolonged exposure to sunlight. Perphenazine has not been shown to be effective for the treatment of behavioral complications in patients with mental retardation. Safety and efficacy in children &lt;12 years of age has not been established.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Cholestatic jaundice, liver damage, and hepatitis may occur; obtain appropriate liver tests; discontinue treatment if liver tests are abnormal. Monitor renal function in patients with long-term therapy; discontinue treatment if BUN becomes abnormal. Phenothiazines may cause anticholinergic effects (confusion, agitation, constipation, xerostomia, blurred vision, urinary retention); therefore, they should be used with caution in patients with decreased GI motility, urinary retention, benign prostatic hypertrophy, xerostomia, or visual problems. Conditions which also may be exacerbated by cholinergic blockade include narrow-angle glaucoma (screening is recommended) and worsening of myasthenia gravis. Relative to other neuroleptics, perphenazine has a low potency of cholinergic blockade.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1030650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause extrapyramidal symptoms, including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia (risk of these reactions is moderate-high relative to other neuroleptics, and is dose-dependent; to decrease risk of tardive dyskinesia: Use smallest dose and shortest duration possible; evaluate continued need periodically; risk of dystonia is increased with the use of high potency and higher doses of conventional antipsychotics and in males and younger patients). May be associated with neuroleptic malignant syndrome (NMS); monitor for mental status changes, fever, muscle rigidity, and/or autonomic instability; risk may be increased in patients with Parkinson's disease or Lewy body dementia. Safety for use during pregnancy and lactation has not been established; prolonged jaundice, hyper-reflexia, hyporeflexia, or extrapyramidal signs may occur in newborn infants of mothers who received phenothiazines; clinical benefits should clearly outweigh risks before initiating use during pregnancy. May cause pigmentary retinopathy; discontinue drug if ophthalmoscopic or visual field exam demonstrated retinal changes.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Leukopenia, neutropenia, and agranulocytosis (sometimes fatal) have been reported in clinical trials and postmarketing reports with antipsychotic use; presence of risk factors (eg, pre-existing low WBC or history of drug-induced leuko/neutropenia) should prompt periodic blood count assessment. Discontinue therapy at first signs of blood dyscrasias or if absolute neutrophil count &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     . Use is contraindicated in patients with existing blood dyscrasias or bone marrow suppression.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     An increased risk of death has been reported with the use of antipsychotics in elderly patients with dementia-related psychosis",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; most deaths seemed to be cardiovascular (eg, sudden death, heart failure) or infectious (eg, pneumonia) in nature; perphenazine is not approved for this indication.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F208649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (major), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F208594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): May enhance the neurotoxic (central) effect of Antipsychotics. Severe extrapyramidal symptoms have occurred in some patients.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antipsychotics may diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): Antipsychotic Agents (Phenothiazines) may enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Serotonin Reuptake Inhibitor/Antagonist): Antipsychotic Agents (Phenothiazines) may enhance the adverse/toxic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist). Specifically, this may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome. Antidepressants (Serotonin Reuptake Inhibitor/Antagonist) may enhance the hypotensive effect of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antimalarial Agents: May increase the serum concentration of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-Parkinson's Agents (Dopamine Agonist): May diminish the therapeutic effect of Antipsychotics (Typical). Antipsychotics (Typical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist). Management: Avoid concomitant therapy if possible and monitor for decreased effects of both agents when these combinations cannot be avoided. Atypical antipsychotics such as clozapine and quetiapine may be less likely to reduce the effects of anti-Parkinson's agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Antipsychotic Agents (Phenothiazines) may enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atenolol; Levobunolol; Metipranolol; Nadolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium formulations: May enhance the neurotoxic effect of Antipsychotics. Lithium formulations may decrease the serum concentration of Antipsychotics. Specifically noted with chlorpromazine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antipsychotics may enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinagolide: Antipsychotics may diminish the therapeutic effect of Quinagolide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: Antipsychotics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F5734286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause increase in dietary riboflavin requirements",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10949611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Jaundice or hyper/hyporeflexia have been reported in newborn infants following maternal use of phenothiazines. Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS]) and withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor; these effects may be self-limiting or require hospitalization.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1030682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs; periodic eye exam, CBC with differential, liver enzyme tests; renal function in patients with long-term use; fasting blood glucose/Hgb A",
"     <sub>",
"      1c",
"     </sub>",
"     ; BMI; therapeutic response (mental status, mood, affect, gait), and adverse reactions at beginning of therapy and periodically with long-term use [eg, excess sedation, extrapyramidal symptoms, tardive dyskinesia, CNS changes, abnormal involuntary movement scale (AIMS)]",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1030668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     2-6 nmol/L",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1030666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Perphenazine is a piperazine phenothiazine antipsychotic which blocks postsynaptic mesolimbic dopaminergic receptors in the brain; exhibits alpha-adrenergic blocking effect and depresses the release of hypothalamic and hypophyseal hormones",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F5163906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: 2-4 weeks for control of psychotic symptoms (hallucinations, disorganized thinking or behavior, delusions)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adequate trial: 6 weeks at moderate to high dose based on tolerability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: Variable",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1030669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Crosses placenta",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic to metabolites via sulfoxidation, hydroxylation, dealkylation, and glucuronidation;",
"     <b>",
"      Note:",
"     </b>",
"     Metabolism is subject to genetic polymorphism; CYP2D6 poor metabolizers will have higher plasma concentrations of perphenazine compared with normal or extensive metabolizers.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Perphenazine: 9-12 hours; 7-hydroxyperphenazine: 9.9-18.8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Perphenazine: 1-3 hours; 7-hydroxyperphenazine: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine and feces, primarily as metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not dialyzable (0% to 5%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1030686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/50/12069?source=see_link\">",
"      see \"Perphenazine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use exactly as directed; do not increase dose or frequency. It may take 2-3 weeks to achieve desired results; do not discontinue without consulting prescriber. Do not take within 2 hours of any antacid. Avoid alcohol, caffeine, and other prescription or nonprescription medications not approved by prescriber. May cause drowsiness, dizziness, lightheadedness, or blurred vision and impair ability to perform activities requiring mental alertness or physical coordination; use caution driving or when engaging in tasks requiring alertness until response to drug is known. May cause dry mouth. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Maintain adequate hydration unless instructed to restrict fluid intake. Avoid skin contact with medication; may cause contact dermatitis (wash immediately with warm, soapy water). May cause nausea, vomiting (small frequent meals, frequent mouth care, chewing gum, or sucking lozenges may help); constipation; postural hypotension (use caution climbing stairs or when changing position from lying or sitting to standing); urinary retention (void before taking medication); or decreased perspiration (avoid strenuous exercise in hot environments). Report persistent CNS effects (eg, trembling fingers, altered gait or balance, excessive sedation, seizures, unusual movements, anxiety, abnormal thoughts, confusion, personality changes); chest pain, palpitations, rapid heartbeat, severe dizziness; unresolved urinary retention or changes in urinary pattern; menstrual pattern, change in libido, swelling or pain in breasts (male or female); vision changes; skin rash or yellowing of skin; respiratory difficulty; or worsening of condition.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F5734287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Long-term usefulness of perphenazine should be periodically re-evaluated in patients receiving the drug for extended periods; consideration should be given whether to decrease the maintenance dose or discontinue drug therapy",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Azaz-Livshits TL, Symmer LI, and Fraenkel YM, &ldquo;Atypical Neuroleptic Malignant Syndrome Presenting as Rhabdomyolysis, Altered Consciousness, and Leukocytosis,&rdquo;",
"      <i>",
"       J Pharm Technol",
"      </i>",
"      , 1995, 11:173-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fujii Y, Saitoh Y, Tanaka H, et al, \"Anti-Emetic Efficacy of Prophylactic Granisetron Compared With Perphenazine for the Prevention of Post-Operative Vomiting in Children,\"",
"      <i>",
"       Eur J Anaesthesiol",
"      </i>",
"      , 1999, 16(5):304-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/6/10343/abstract-text/10390665/pubmed\" id=\"10390665\" target=\"_blank\">",
"        10390665",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fujii Y, Saitoh Y, Tanaka H, et al, \"Preoperative Oral Antiemetics for Reducing Postoperative Vomiting After Tonsillectomy in Children: Granisetron Versus Perphenazine,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1999a, 88(6):1298-301.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/6/10343/abstract-text/10357333/pubmed\" id=\"10357333\" target=\"_blank\">",
"        10357333",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hansen LB and Larsen NE, &ldquo;Metabolic Interaction Between Perphenazine and Disulfiram,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1982, 2(8313):1472.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/6/10343/abstract-text/6129552/pubmed\" id=\"6129552\" target=\"_blank\">",
"        6129552",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Harper G, Dawes M, Azlin C, et al, &ldquo;Small Bowel Obstruction in a Child on an Antipsychotic,&rdquo;",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 1995, 5:81-4.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lieberman JA, Stroup TS, McEvoy JP, et al, \"Effectiveness of Antipsychotic Drugs in Patients With Chronic Schizophrenia,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 353(12):1209-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/6/10343/abstract-text/16172203/pubmed\" id=\"16172203\" target=\"_blank\">",
"        16172203",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miyamoto S, Duncan GE, Marx CE, et al, \"Treatments for Schizophrenia: A Critical Review of Pharmacology and Mechanisms of Action of Antipsychotic Drugs,\"",
"      <i>",
"       Mol Psychiatry",
"      </i>",
"      , 2005, 10(1):79-104.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/6/10343/abstract-text/15289815/pubmed\" id=\"15289815\" target=\"_blank\">",
"        15289815",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Remington G, \"Tardive Dyskinesia: Eliminated, Forgotten, or Overshadowed?\"",
"      <i>",
"       Curr Opin Psychiatry",
"      </i>",
"      , 2007, 20(2):131-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/6/10343/abstract-text/17278910/pubmed\" id=\"17278910\" target=\"_blank\">",
"        17278910",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Splinter WM and Roberts DJ, \"Perphenazine Decreases Vomiting by Children After Tonsillectomy,\"",
"      <i>",
"       Can J Anaesth",
"      </i>",
"      , 1997, 44(12):1308-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/6/10343/abstract-text/9429051/pubmed\" id=\"9429051\" target=\"_blank\">",
"        9429051",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Splinter WM and Roberts DJ, \"Prophylaxis for Vomiting by Children After Tonsillectomy: Dexamethasone Versus Perphenazine,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1997a, 85(3):534-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/6/10343/abstract-text/9296405 /pubmed\" id=\"9296405 \" target=\"_blank\">",
"        9296405",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Splinter WM and Rhine EJ, \"Prophylaxis for Vomiting by Children After Tonsillectomy: Ondansetron Compared With Perphenazine,\"",
"      <i>",
"       Br J Anaesth",
"      </i>",
"      , 1998, 80(2):155-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/6/10343/abstract-text/9602577/pubmed\" id=\"9602577\" target=\"_blank\">",
"        9602577",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13069 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.181.191-9843F0D5B8-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_6_10343=[""].join("\n");
var outline_f10_6_10343=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7290569\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208621\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1030644\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1030676\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208600\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208585\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5948059\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1030664\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1030645\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208662\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208660\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1030649\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5734285\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1030650\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208649\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208594\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5734286\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10949611\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1030682\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1030668\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1030666\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5163906\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1030669\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1030686\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5734287\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13069\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13069|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/49/19223?source=related_link\">",
"      Perphenazine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/50/12069?source=related_link\">",
"      Perphenazine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_6_10344="Right bundle branch block";
var content_f10_6_10344=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Right bundle branch block",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/6/10344/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/6/10344/contributors\">",
"     William H Sauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/6/10344/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/6/10344/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/6/10344/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/6/10344/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/6/10344/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Right bundle branch block (RBBB), a pattern seen on the surface electrocardiogram (ECG), results when normal electrical activity in the His-Purkinje system is interrupted (",
"    <a class=\"graphic graphic_figure graphicRef63340 \" href=\"UTD.htm?42/52/43841\">",
"     figure 1",
"    </a>",
"    ). The normal sequence of activation is altered dramatically in RBBB, with a resultant characteristic appearance on the ECG manifest by a widened QRS complex and changes in the directional vectors of the R and S waves (",
"    <a class=\"graphic graphic_waveform graphicRef64393 \" href=\"UTD.htm?42/12/43210\">",
"     waveform 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H14316065\">",
"     'Electrocardiographic findings'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The anatomy, clinical manifestations, differential diagnosis, prognostic implications, and treatment of RBBB will be reviewed here. Additional details regarding the ECG manifestations of RBBB are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/33/22038?source=see_link&amp;anchor=H3#H3\">",
"     \"ECG tutorial: Intraventricular block\", section on 'Right bundle branch block'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14315697\">",
"    <span class=\"h1\">",
"     ANATOMY AND ELECTROPHYSIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14315705\">",
"    <span class=\"h2\">",
"     Anatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bundle of His divides at the juncture of the fibrous and muscular boundaries of the intraventricular septum into the left and right bundle branches (",
"    <a class=\"graphic graphic_figure graphicRef63340 \" href=\"UTD.htm?42/52/43841\">",
"     figure 1",
"    </a>",
"    ). The right bundle branch is a long, thin, discrete structure that consists of fast response Purkinje fibers. The right bundle branch courses down the right side of interventricular septum near the endocardium in its upper third, deeper in the muscular portion of the septum in the middle third, and then again near the endocardium in its lower third. The right bundle branch does not divide throughout most of its course, but begins to ramify as it approaches the base of the right anterior papillary muscle with fascicles going to the septal and free walls of the right ventricle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14315874\">",
"    <span class=\"h2\">",
"     Blood supply",
"    </span>",
"    &nbsp;&mdash;&nbsp;The right bundle branch receives most of its blood supply from septal branches of the left anterior descending coronary artery, particularly in its initial course. In most patients, it also receives some collateral supply from either the right or circumflex coronary systems depending upon the dominance of the coronary system (",
"    <a class=\"graphic graphic_figure graphicRef70956 \" href=\"UTD.htm?21/44/22213\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14315790\">",
"    <span class=\"h2\">",
"     Electrophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The right bundle branch consists of a bundle of Purkinje cells covered by a dense sheath of connective tissue. Purkinje cells are specialized to conduct rapidly at 1 to 3",
"    <span class=\"nowrap\">",
"     m/sec,",
"    </span>",
"    as phase 0 is dependent on the rapid inward sodium current (",
"    <a class=\"graphic graphic_figure graphicRef64133 \" href=\"UTD.htm?26/24/27023\">",
"     figure 3",
"    </a>",
"    ). Initial activation occurs near the apex of the right ventricular endocardium, subsequently spreading to the septum and the free wall of the right ventricle, then moving much more slowly through the myocardial cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38422?source=see_link\">",
"     \"Myocardial action potential and action of antiarrhythmic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intraoperative studies in humans have shown that right bundle branch block (RBBB) can occur at three discrete levels [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10344/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The proximal right bundle, which is the most common site of RBBB.",
"     </li>",
"     <li>",
"      The distal right bundle, which is unusual unless there has been transection of the moderator band during surgery.",
"     </li>",
"     <li>",
"      The terminal right bundle, which may be produced by ventriculotomy or transatrial resection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, RBBB may be induced by disease in the His bundle, resulting in activation that is asynchronous from that in the rest of the infranodal conducting system, possibly resulting in a bundle branch or fascicular block [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10344/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of RBBB increases with age. In one prospective study of 855 men followed for 30 years, the prevalence was 0.8 percent in subjects at age 50 and 11.3 percent by age 80 (",
"    <a class=\"graphic graphic_figure graphicRef70445 \" href=\"UTD.htm?29/9/29854\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10344/abstract/6\">",
"     6",
"    </a>",
"    ]. There was no significant association with risk factors for, or the presence of, ischemic heart disease, myocardial infarction, or cardiovascular deaths, suggesting that RBBB is usually a marker of a slowly progressive degenerative disease that also affects the myocardium. Similar observations apply to left bundle branch block [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10344/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39784?source=see_link\">",
"     \"Left bundle branch block\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    RBBB can rarely occur in an otherwise normal heart, with a prevalence estimated between 0.2 and 1.3 percent, as illustrated by the following observations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10344/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 237,000 airmen under age 30; there were 394 cases of complete RBBB, representing a prevalence of 0.2 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?10/6/10344/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a series of 7392 men ages 45 to 55 years without myocardial infarction or stroke, RBBB was present in 50 (0.7 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/6/10344/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 66,450 participants in the Women's Health Initiative trial, 832 had RBBB at study entry, representing a prevalence of 1.3 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?10/6/10344/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Incomplete RBBB (QRS duration between 100 and 119 msec) can also be seen in apparently healthy persons, and in contrast to complete RBBB, it appears to be less common with advancing age. In a study of 43,401 Swiss military conscripts (mean age 19.1 years), incomplete RBBB was the most common ECG abnormality, seen in 13.5 percent of the cohort, while among 18,441 participants (mean age 50.1 years) in the Copenhagen City Heart Study, 3.4 percent had an incomplete RBBB [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10344/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The right bundle branch is vulnerable to stretch and trauma for two-thirds of its course when it is near the subendocardial surface (",
"    <a class=\"graphic graphic_figure graphicRef63340 \" href=\"UTD.htm?42/52/43841\">",
"     figure 1",
"    </a>",
"    ). Conduction in the right bundle can be compromised by both structural and functional factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Structural heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac conditions that can cause RBBB include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronically increased right ventricular pressure, as in cor pulmonale, which may also be associated with electrocardiographic findings of right ventricular hypertrophy (",
"      <a class=\"graphic graphic_waveform graphicRef67622 \" href=\"UTD.htm?43/21/44378\">",
"       waveform 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/17/36119?source=see_link&amp;anchor=H8#H8\">",
"       \"Cor pulmonale\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A sudden increase in right ventricular pressure with stretch, as in pulmonary embolism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=see_link&amp;anchor=H7#H7\">",
"       \"Diagnosis of acute pulmonary embolism\", section on 'Electrocardiography'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Myocardial ischemia, infarction, or inflammation (as in myocarditis). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4282?source=see_link\">",
"       \"Conduction abnormalities after myocardial infarction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26889?source=see_link&amp;anchor=H16#H16\">",
"       \"Clinical manifestations and diagnosis of myocarditis in adults\", section on 'Electrocardiogram'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other less common causes of RBBB include hypertension, cardiomyopathies, and congenital heart disease. RBBB can also result from idiopathic progressive cardiac conduction disease (also called Lenegre's disease or Lev's disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10344/abstract/8,13,14\">",
"     8,13,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32007?source=see_link&amp;anchor=H4#H4\">",
"     \"Etiology of atrioventricular block\", section on 'Idiopathic progressive cardiac conduction disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Iatrogenic RBBB",
"    </span>",
"    &nbsp;&mdash;&nbsp;RBBB can also be caused by procedures and interventions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Right heart catheter insertion results in transient RBBB in approximately 5 percent of cases. In this setting, RBBB is related to minor catheter trauma to the conduction system, which is usually transient and relieved by removal of the catheter. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=see_link&amp;anchor=H9#H9\">",
"       \"Pulmonary artery catheterization: Indications and complications\", section on 'Insertion'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nonsurgical septal reduction therapy with ethanol ablation, used in patients with hypertrophic cardiomyopathy and left ventricular outflow tract obstruction, results in RBBB in approximately 50 percent of cases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7514?source=see_link&amp;anchor=H16#H16\">",
"       \"Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy\", section on 'Alcohol (ethanol) septal ablation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Functional RBBB",
"    </span>",
"    &nbsp;&mdash;&nbsp;RBBB may be functional, as a result of a long preceding R-R interval following by a short cycle (\"rate-related bundle branch block\"). Functional RBBB may be sustained if, after the initial aberration, the impulse down the left bundle reenters the right bundle branch rendering it again refractory, and this pattern repeats for several cycles.",
"   </p>",
"   <p>",
"    Ventricular tachycardia may mimic RBBB, as in idiopathic left ventricular tachycardia with right bundle branch block morphology and left axis deviation (Belhassen type) or in bundle branch reentrant ventricular tachycardia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26858?source=see_link\">",
"     \"Monomorphic ventricular tachycardia in the absence of apparent structural heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41637?source=see_link\">",
"     \"Bundle branch reentrant ventricular tachycardia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hyperkalemia can depress conduction in the His-Purkinje system and rarely causes RBBB [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10344/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35558?source=see_link&amp;anchor=H11#H11\">",
"     \"ECG tutorial: Miscellaneous diagnoses\", section on 'Hyperkalemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pseudo RBBB pattern",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with uncommon primary ventricular arrhythmia syndromes (ie, Brugada syndrome, arrhythmogenic right ventricular cardiomyopathy) have ECG patterns similar to RBBB. However, these patients have distinct types of right ventricular myocardial disease that produce an ECG pattern similar to RBBB and should not be considered to have true RBBB. (See",
"    <a class=\"local\" href=\"#H14316219\">",
"     'Differential diagnosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=see_link\">",
"     \"Brugada syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=see_link\">",
"     \"Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14316065\">",
"    <span class=\"h1\">",
"     ELECTROCARDIOGRAPHIC FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;To best understand the electrocardiographic (ECG) findings in RBBB, one should have a basic understanding of the vectors involved in electrocardiography as well as the basic conventions of nomenclature used in electrocardiography. This information is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/33/22038?source=see_link&amp;anchor=H3#H3\">",
"     \"ECG tutorial: Intraventricular block\", section on 'Right bundle branch block'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most of the ECG findings with RBBB are related to the QRS complex. However, some accompanying changes may also be seen in the ST segment and T wave.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14316091\">",
"    <span class=\"h2\">",
"     QRS complex",
"    </span>",
"    &nbsp;&mdash;&nbsp;A task force from the American Heart Association, the American College of Cardiology, and the Heart Rhythm Society has defined the electrocardiographic features of RBBB [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10344/abstract/17\">",
"     17",
"    </a>",
"    ]. These criteria incorporate the activation forces described above and include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      QRS duration greater than or equal to 120 msec in adults.",
"     </li>",
"     <li>",
"      Rsr', rsR', or rSR' in leads V1 or V2. The R' or r' deflection is usually wider than the initial R wave. In a minority of patients, a wide and often notched R wave pattern may be seen in lead V1",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      V2.",
"     </li>",
"     <li>",
"      S wave of greater duration than R wave or greater than 40 msec in leads I and V6 in adults.",
"     </li>",
"     <li>",
"      Normal R peak time in leads V5 and V6 but greater than 50 msec in lead V1 (associated with the R' wave).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14316112\">",
"    <span class=\"h2\">",
"     ST segment and T waves",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accompanying ST segment and T wave changes are due to an altered sequence of repolarization. The ST segment change is usually small, but, when present, it is discordant (ie, has an axis in the opposite direction) to the terminal mean QRS spatial vector. The T wave also tends to be discordant to the terminal conduction disturbance, resulting in inverted T waves in the right precordial leads (where there is a terminal R' wave) and upright T waves in the left precordial leads (where there is a terminal S wave).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H279462\">",
"    <span class=\"h2\">",
"     Other diagnostic considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several other diagnostic considerations in the ECG interpretation of RBBB:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      RBBB does",
"      <strong>",
"       not",
"      </strong>",
"      interfere with the diagnosis of coexistent myocardial infarction on the basis of the usual Q and R wave criteria, since the vectorial forces of the initial 0.03 to 0.04 seconds are essentially normal [",
"      <a class=\"abstract\" href=\"UTD.htm?10/6/10344/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increased right ventricular pressures may cause the initial vector to swing superiorly and posteriorly, which may produce q waves in the inferior and right precordial leads. This can occasionally simulate the changes seen with inferior and anterior myocardial infarction.",
"     </li>",
"     <li>",
"      There is a low sensitivity in the voltage criteria for left ventricular enlargement due to the late anterior forces and due to the reduction of amplitude of the S wave in the right precordial leads [",
"      <a class=\"abstract\" href=\"UTD.htm?10/6/10344/abstract/19,20\">",
"       19,20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14316219\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;While RBBB has a fairly characteristic appearance on ECG, there are other conditions in which the ECG may have a similar appearance that need to be excluded prior to the diagnosis of RBBB.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H279419\">",
"    <span class=\"h2\">",
"     Incomplete RBBB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delay in the right bundle conduction ranges from trivial to severe, producing a similar spectrum displacement and duration of the rightward terminal conduction disturbance. RBBB is arbitrarily said to be \"complete\" when the QRS duration is over 0.12 sec and \"incomplete\" when it is between 0.10 and 0.11 sec. A RBBB pattern with a QRS duration less than 0.10 sec may be a normal variant, presumably reflecting a slight delay in the terminal posterobasal forces in some individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H279315\">",
"    <span class=\"h2\">",
"     Ventricular tachycardia and accelerated idioventricular rhythm",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the dominant ventricular rhythm originates from a pacemaker in the ventricle, the QRS will be widened and can have the appearance of a RBBB. However, both ventricular tachycardia (heart rate greater than 100 beats per minute) (",
"    <a class=\"graphic graphic_waveform graphicRef63176 \" href=\"UTD.htm?28/0/28680\">",
"     waveform 3",
"    </a>",
"    ) and accelerated idioventricular rhythm (heart rate between 60 and 100 beats per minute) (",
"    <a class=\"graphic graphic_waveform graphicRef52385 \" href=\"UTD.htm?39/57/40856\">",
"     waveform 4",
"    </a>",
"    ) are associated with atrioventricular (AV) dissociation, which should distinguish the rhythm from a supraventricular rhythm with aberrant conduction seen with RBBB. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/8/43144?source=see_link\">",
"     \"Sustained monomorphic ventricular tachycardia: Diagnosis and evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1942?source=see_link&amp;anchor=H11#H11\">",
"     \"ECG tutorial: Ventricular arrhythmias\", section on 'Accelerated idioventricular rhythm'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H279352\">",
"    <span class=\"h2\">",
"     Ventricular pacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular pacing from the right ventricular apex typically results in a QRS complex resembling that seen with left bundle branch block (LBBB) on the surface ECG. However, the QRS complex resulting from biventricular pacing is more complicated and may sometimes give the appearance of a RBBB (",
"    <a class=\"graphic graphic_waveform graphicRef64812 \" href=\"UTD.htm?25/15/25844\">",
"     waveform 5",
"    </a>",
"    ). When a paced QRS complex has a RBBB morphology in the absence of an LV lead, the possibility of RV lead perforation or inadvertent LV lead placement must be considered. In nearly all patients, however, the presence of pacemaker spikes preceding the QRS complex differentiates a paced complex from a RBBB.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H279217\">",
"    <span class=\"h2\">",
"     Brugada syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Brugada syndrome is associated with particular ECG changes and an increased risk of sudden death. The ECG pattern of Brugada syndrome occurs in less than 0.2 percent of individuals overall but in as many as 3 to 24 percent of those presenting with idiopathic ventricular fibrillation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=see_link\">",
"     \"Brugada syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ECG in Brugada syndrome consists of a pseudo-RBBB pattern and ST-segment elevation in leads V1 to V3 (",
"    <a class=\"graphic graphic_waveform graphicRef64510 \" href=\"UTD.htm?8/35/8762\">",
"     waveform 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10344/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. The ST-segment elevation usually slopes downward, and the T wave is inverted. The widened S wave in left lateral leads that is characteristic of typical RBBB is absent in most patients with Brugada syndrome. This observation suggests that there is a high takeoff of the ST segment in the right precordium (ie, a \"J\" wave) rather than a true RBBB [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10344/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some patients, the ST segment abnormalities are transient but can be exposed by a sodium channel blocker, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    , ajmaline, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10344/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis in patients with RBBB is related largely to the presence, type, and severity of underlying heart disease or associated conduction abnormalities:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with known or suspected cardiovascular disease (CVD), RBBB is an independent predictor of all-cause mortality. Several large cohort studies have shown an increase in mortality among patients with CVD and complete RBBB [",
"      <a class=\"abstract\" href=\"UTD.htm?10/6/10344/abstract/10,26-28\">",
"       10,26-28",
"      </a>",
"      ]. As an example, among 12,346 women with CVD (excluding those with LBBB) who participated in the Women's Health Initiative trial, there was a significantly greater risk of death from coronary heart disease (adjusted hazard ratio [HR] 1.62, 95% CI 1.08-2.43) but not overall mortality (adjusted HR 1.10, 95% CI 0.84-1.44) among women with RBBB compared with no BBB [",
"      <a class=\"abstract\" href=\"UTD.htm?10/6/10344/abstract/10\">",
"       10",
"      </a>",
"      ]. The presence of RBBB after a myocardial infarction is also associated with an increase in mortality. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4282?source=see_link&amp;anchor=H18#H18\">",
"       \"Conduction abnormalities after myocardial infarction\", section on 'Bundle branch block'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The presence of a RBBB in the setting of an acute myocardial infarction is associated with a significant increase in mortality, even when thrombolytic therapy has been administered. This issue is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4282?source=see_link\">",
"       \"Conduction abnormalities after myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with heart failure, there is an association between RBBB and higher mortality compared with those without a bundle branch block. In one study of 1888 patients with a recent heart failure hospitalization, RBBB was associated with worse long-term outcomes over a follow-up of four years [",
"      <a class=\"abstract\" href=\"UTD.htm?10/6/10344/abstract/29\">",
"       29",
"      </a>",
"      ]. This was also seen in 2907 consecutive patients admitted to an intensive care unit with decompensated heart failure [",
"      <a class=\"abstract\" href=\"UTD.htm?10/6/10344/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients who also have type II second degree atrioventricular (AV) block or multi-fascicular block generally have more significant myocardial disease and a guarded prognosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/62/998?source=see_link\">",
"       \"Second degree atrioventricular block: Mobitz type II\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12261?source=see_link\">",
"       \"Course and treatment of chronic bifascicular block\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Long-term outcomes are generally excellent in patients with RBBB and without apparent heart disease, although one report has suggested an increase in all-cause and cardiac mortality in persons with a RBBB [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10344/abstract/8,9,31-36\">",
"     8,9,31-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a primary prevention study from Sweden in which 7392 middle-aged men were followed for 28 years, men with RBBB had a nonsignificant increase in progression to high-degree AV block and no increase in myocardial infarction (MI) or coronary or all-cause mortality compared to men without bundle branch block [",
"      <a class=\"abstract\" href=\"UTD.htm?10/6/10344/abstract/9\">",
"       9",
"      </a>",
"      ]. Similarly, among 53,197 women free of CVD (excluding those with LBBB) upon entry into the Women's Health Initiative trial, there was no significant increase in either death from coronary heart disease (adjusted HR 1.31, 95% CI 0.77-2.23) or death from any cause (adjusted HR 0.89, 95% CI 0.67-1.19) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/6/10344/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, among 18,441 participants in the Copenhagen City Heart Study without a prior MI, heart failure, or LBBB who were followed for over 20 years, persons with RBBB had significantly greater all-cause and cardiovascular mortality compared with those without RBBB (adjusted HR 1.31, 95% CI 1.11-1.54 for all-cause mortality and 1.87, 95% CI 1.48-2.36 for cardiovascular mortality, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/6/10344/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     EVALUATION AND TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with isolated chronic RBBB are generally asymptomatic and do not require further diagnostic evaluation for RBBB or placement of a pacemaker or any other specific therapy. However, a pacemaker may be needed if syncope occurs, particularly if other conduction disturbances are present, such as third degree or type II second degree AV block.",
"   </p>",
"   <p>",
"    Although the presence of RBBB in the setting of low left ventricular ejection fraction and heart failure is an indication for cardiac resynchronization therapy (because these patients were included as part of these clinical trials), it remains unclear whether these patients respond to the same degree as those with LBBB. Several studies have demonstrated the association between RBBB and poorer outcomes after cardiac resynchronization therapy compared to those with LBBB [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10344/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/36/10823?source=see_link\">",
"     \"Rationale for and mechanisms of benefit of cardiac resynchronization therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Indications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with pre-existing left bundle branch block who require right heart catheter placement are at risk for complete heart block if RBBB develops. Although the risk is low and complete heart block is usually transient, catheter insertion should not be undertaken in patients with LBBB without the ability to institute immediate transcutaneous or transvenous cardiac pacing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=see_link&amp;anchor=H9#H9\">",
"     \"Pulmonary artery catheterization: Indications and complications\", section on 'Insertion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H647184\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Right bundle branch block (RBBB) results when normal electrical activity in the His-Purkinje system is interrupted, thereby altering the normal sequence of activation, resulting in the characteristic electrocardiographic (ECG) appearance of a widened QRS complex and changes in the directional vectors of the R and S waves (",
"      <a class=\"graphic graphic_waveform graphicRef64393 \" href=\"UTD.htm?42/12/43210\">",
"       waveform 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14316065\">",
"       'Electrocardiographic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The bundle of His divides at the juncture of the fibrous and muscular boundaries of the intraventricular septum into the left and right bundle branches (",
"      <a class=\"graphic graphic_figure graphicRef63340 \" href=\"UTD.htm?42/52/43841\">",
"       figure 1",
"      </a>",
"      ). The right bundle branch is a long, thin, discrete structure that courses down the right side of interventricular septum, receiving most of its blood supply from the left anterior descending coronary artery, although in most patients, it also receives some collateral supply from either the right or circumflex coronary systems. (See",
"      <a class=\"local\" href=\"#H14315697\">",
"       'Anatomy and electrophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevalence of RBBB, which appears to increase with age, has been estimated between 0.2 to 0.8 percent of the general population. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Various clinical conditions are associated with the development of RBBB or other electrocardiographic findings similar to RBBB:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      RBBB is associated with several types of structural heart disease including cor pulmonale, pulmonary embolism, myocardial",
"      <span class=\"nowrap\">",
"       ischemia/infarction,",
"      </span>",
"      myocarditis, hypertension, and congenital heart disease. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Structural heart disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      RBBB can develop iatrogenically in patients undergoing right heart catheterization or ethanol ablation of the basal ventricular septum. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Iatrogenic RBBB'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The electrocardiographic features of the QRS complex which define RBBB in adults include QRS duration greater than or equal to 120 msec, rsr&rsquo;, rsR&rsquo;, or rSR&rsquo; in leads V1 or V2, S wave of greater duration than R wave or greater than 40 msec in leads I and V6, and normal R peak time in leads V5 and V6 but greater than 50 msec in lead V1. Accompanying ST segment and T wave changes are due to an altered sequence of repolarization. (See",
"      <a class=\"local\" href=\"#H14316065\">",
"       'Electrocardiographic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      RBBB does",
"      <strong>",
"       not",
"      </strong>",
"      interfere with the diagnosis of coexistent myocardial infarction on the basis of the usual Q and R wave criteria, since the vectorial forces of the initial 0.03 to 0.04 seconds are essentially normal. (See",
"      <a class=\"local\" href=\"#H279462\">",
"       'Other diagnostic considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ventricular rhythms, ventricular pacing, and the Brugada syndrome, conditions in which the QRS complex has a similar morphology to RBBB, need to be excluded prior to making the diagnosis of RBBB. (See",
"      <a class=\"local\" href=\"#H14316219\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prognosis in patients with RBBB is related largely to the type and severity of any concurrent underlying heart disease and to the possible presence of other conduction disturbances. Long-term outcomes are generally excellent in patients without apparent heart disease, while those with RBBB in the setting of underlying cardiac disease generally have worse outcomes than those without bundle branch block. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For asymptomatic patients with an isolated RBBB and no other evidence of cardiac disease, no further diagnostic evaluation or specific therapy is required. However, permanent pacemaker insertion is indicated for patients with RBBB who develop symptomatic conduction system disturbances, such as third degree or type II second degree AV block that is not associated with a reversible or transient condition. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Evaluation and treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10344/abstract/1\">",
"      Horowitz LN, Alexander JA, Edmunds LH Jr. Postoperative right bundle branch block: identification of three levels of block. Circulation 1980; 62:319.",
"     </a>",
"    </li>",
"    <li>",
"     Josephson, ME. Clinical Cardiac Electrophysiology: Techniques and Interpretations, 2nd, Lea &amp; Febiger, Philadelphia 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10344/abstract/3\">",
"      Watt TB Jr, Pruitt RD. Focal lesions in the canine bundle of His. Their effect on ventricular excitation. Circ Res 1972; 31:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10344/abstract/4\">",
"      Narula OS. Longitudinal dissociation in the His bundle. Bundle branch block due to asynchronous conduction within the His bundle in man. Circulation 1977; 56:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10344/abstract/5\">",
"      El-Sherif N, Amay-Y-Leon F, Schonfield C, et al. Normalization of bundle branch block patterns by distal His bundle pacing. Clinical and experimental evidence of longitudinal dissociation in the pathologic his bundle. Circulation 1978; 57:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10344/abstract/6\">",
"      Eriksson P, Hansson PO, Eriksson H, Dellborg M. Bundle-branch block in a general male population: the study of men born 1913. Circulation 1998; 98:2494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10344/abstract/7\">",
"      HISS RG, LAMB LE. Electrocardiographic findings in 122,043 individuals. Circulation 1962; 25:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10344/abstract/8\">",
"      Rotman M, Triebwasser JH. A clinical and follow-up study of right and left bundle branch block. Circulation 1975; 51:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10344/abstract/9\">",
"      Eriksson P, Wilhelmsen L, Rosengren A. Bundle-branch block in middle-aged men: risk of complications and death over 28 years. The Primary Prevention Study in G&ouml;teborg, Sweden. Eur Heart J 2005; 26:2300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10344/abstract/10\">",
"      Zhang ZM, Rautaharju PM, Soliman EZ, et al. Mortality risk associated with bundle branch blocks and related repolarization abnormalities (from the Women's Health Initiative [WHI]). Am J Cardiol 2012; 110:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10344/abstract/11\">",
"      Kobza R, Cuculi F, Ab&auml;cherli R, et al. Twelve-lead electrocardiography in the young: physiologic and pathologic abnormalities. Heart Rhythm 2012; 9:2018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10344/abstract/12\">",
"      Bussink BE, Holst AG, Jespersen L, et al. Right bundle branch block: prevalence, risk factors, and outcome in the general population: results from the Copenhagen City Heart Study. Eur Heart J 2013; 34:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10344/abstract/13\">",
"      LENEGRE J. ETIOLOGY AND PATHOLOGY OF BILATERAL BUNDLE BRANCH BLOCK IN RELATION TO COMPLETE HEART BLOCK. Prog Cardiovasc Dis 1964; 6:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10344/abstract/14\">",
"      LEV M. ANATOMIC BASIS FOR ATRIOVENTRICULAR BLOCK. Am J Med 1964; 37:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10344/abstract/15\">",
"      Ohmae M, Rabkin SW. Hyperkalemia-induced bundle branch block and complete heart block. Clin Cardiol 1981; 4:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10344/abstract/16\">",
"      Bashour T, Hsu I, Gorfinkel HJ, et al. Atrioventricular and intraventricular conduction in hyperkalemia. Am J Cardiol 1975; 35:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10344/abstract/17\">",
"      Surawicz B, Childers R, Deal BJ, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part III: intraventricular conduction disturbances: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol 2009; 53:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10344/abstract/18\">",
"      Wagner GS, Macfarlane P, Wellens H, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part VI: acute ischemia/infarction: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol 2009; 53:1003.",
"     </a>",
"    </li>",
"    <li>",
"     Lopes MG, Pereirinha A, DePadua F. The diagnosis of left ventricular hypertrophy in the presence of bundle branch block &mdash; An ECG/VCG and echocardiographic correlation. In: Modern Electrocardiology, Antaloczy Z (Ed), Excerpta Medica, Amsterdam 1978. p.423.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10344/abstract/20\">",
"      Hancock EW, Deal BJ, Mirvis DM, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part V: electrocardiogram changes associated with cardiac chamber hypertrophy: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol 2009; 53:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10344/abstract/21\">",
"      Gussak I, Antzelevitch C, Bjerregaard P, et al. The Brugada syndrome: clinical, electrophysiologic and genetic aspects. J Am Coll Cardiol 1999; 33:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10344/abstract/22\">",
"      Alings M, Wilde A. \"Brugada\" syndrome: clinical data and suggested pathophysiological mechanism. Circulation 1999; 99:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10344/abstract/23\">",
"      Naccarelli GV, Antzelevitch C, Wolbrette DL, Luck JC. The Brugada syndrome. Curr Opin Cardiol 2002; 17:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10344/abstract/24\">",
"      Krishnan SC, Josephson ME. ST segment elevation induced by class IC antiarrhythmic agents: underlying electrophysiologic mechanisms and insights into drug-induced proarrhythmia. J Cardiovasc Electrophysiol 1998; 9:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10344/abstract/25\">",
"      Brugada R, Brugada J, Antzelevitch C, et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation 2000; 101:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10344/abstract/26\">",
"      Hesse B, Diaz LA, Snader CE, et al. Complete bundle branch block as an independent predictor of all-cause mortality: report of 7,073 patients referred for nuclear exercise testing. Am J Med 2001; 110:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10344/abstract/27\">",
"      Freedman RA, Alderman EL, Sheffield LT, et al. Bundle branch block in patients with chronic coronary artery disease: angiographic correlates and prognostic significance. J Am Coll Cardiol 1987; 10:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10344/abstract/28\">",
"      Sumner G, Salehian O, Yi Q, et al. The prognostic significance of bundle branch block in high-risk chronic stable vascular disease patients: a report from the HOPE trial. J Cardiovasc Electrophysiol 2009; 20:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10344/abstract/29\">",
"      Barsheshet A, Goldenberg I, Garty M, et al. Relation of bundle branch block to long-term (four-year) mortality in hospitalized patients with systolic heart failure. Am J Cardiol 2011; 107:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10344/abstract/30\">",
"      McCullough PA, Hassan SA, Pallekonda V, et al. Bundle branch block patterns, age, renal dysfunction, and heart failure mortality. Int J Cardiol 2005; 102:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10344/abstract/31\">",
"      Taniguchi M, Nakano H, Kuwahara K, et al. Prognostic and clinical significance of newly acquired complete right bundle branch block in Japan Airline pilots. Intern Med 2003; 42:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10344/abstract/32\">",
"      Kim JH, Noseworthy PA, McCarty D, et al. Significance of electrocardiographic right bundle branch block in trained athletes. Am J Cardiol 2011; 107:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10344/abstract/33\">",
"      Thrainsdottir IS, Hardarson T, Thorgeirsson G, et al. The epidemiology of right bundle branch block and its association with cardiovascular morbidity--the Reykjavik Study. Eur Heart J 1993; 14:1590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10344/abstract/34\">",
"      Fahy GJ, Pinski SL, Miller DP, et al. Natural history of isolated bundle branch block. Am J Cardiol 1996; 77:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10344/abstract/35\">",
"      Miller WL, Hodge DO, Hammill SC. Association of uncomplicated electrocardiographic conduction blocks with subsequent cardiac morbidity in a community-based population (Olmsted County, Minnesota). Am J Cardiol 2008; 101:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10344/abstract/36\">",
"      Aro AL, Anttonen O, Tikkanen JT, et al. Intraventricular conduction delay in a standard 12-lead electrocardiogram as a predictor of mortality in the general population. Circ Arrhythm Electrophysiol 2011; 4:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10344/abstract/37\">",
"      Bilchick KC, Kamath S, DiMarco JP, Stukenborg GJ. Bundle-branch block morphology and other predictors of outcome after cardiac resynchronization therapy in Medicare patients. Circulation 2010; 122:2022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10344/abstract/38\">",
"      Rickard J, Kumbhani DJ, Gorodeski EZ, et al. Cardiac resynchronization therapy in non-left bundle branch block morphologies. Pacing Clin Electrophysiol 2010; 33:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10344/abstract/39\">",
"      Egoavil CA, Ho RT, Greenspon AJ, Pavri BB. Cardiac resynchronization therapy in patients with right bundle branch block: analysis of pooled data from the MIRACLE and Contak CD trials. Heart Rhythm 2005; 2:611.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 915 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-2E861B2D37-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_6_10344=[""].join("\n");
var outline_f10_6_10344=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H647184\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14315697\">",
"      ANATOMY AND ELECTROPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14315705\">",
"      Anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14315874\">",
"      Blood supply",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14315790\">",
"      Electrophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Iatrogenic RBBB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Functional RBBB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pseudo RBBB pattern",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14316065\">",
"      ELECTROCARDIOGRAPHIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14316091\">",
"      QRS complex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14316112\">",
"      ST segment and T waves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H279462\">",
"      Other diagnostic considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14316219\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H279419\">",
"      Incomplete RBBB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H279315\">",
"      Ventricular tachycardia and accelerated idioventricular rhythm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H279352\">",
"      Ventricular pacing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H279217\">",
"      Brugada syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EVALUATION AND TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H647184\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/915\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/915|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/52/43841\" title=\"figure 1\">",
"      Normal conduction system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/44/22213\" title=\"figure 2\">",
"      Coronary artery anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/24/27023\" title=\"figure 3\">",
"      Action potential and ECG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/9/29854\" title=\"figure 4\">",
"      Incidence outcome BBB",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/915|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/12/43210\" title=\"waveform 1\">",
"      Right bundle branch block 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?43/21/44378\" title=\"waveform 2\">",
"      ECG of right ventricular hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?28/0/28680\" title=\"waveform 3\">",
"      ECG Monomorphic VT tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?39/57/40856\" title=\"waveform 4\">",
"      ECG Accelerated idioventricular rhythm tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?25/15/25844\" title=\"waveform 5\">",
"      Biventricular pacing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?8/35/8762\" title=\"waveform 6\">",
"      ECG Brugada syndrome type I pattern",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=related_link\">",
"      Brugada syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41637?source=related_link\">",
"      Bundle branch reentrant ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=related_link\">",
"      Cardiac resynchronization therapy in heart failure: Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=related_link\">",
"      Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26889?source=related_link\">",
"      Clinical manifestations and diagnosis of myocarditis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4282?source=related_link\">",
"      Conduction abnormalities after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/17/36119?source=related_link\">",
"      Cor pulmonale",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12261?source=related_link\">",
"      Course and treatment of chronic bifascicular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/33/22038?source=related_link\">",
"      ECG tutorial: Intraventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35558?source=related_link\">",
"      ECG tutorial: Miscellaneous diagnoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1942?source=related_link\">",
"      ECG tutorial: Ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32007?source=related_link\">",
"      Etiology of atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39784?source=related_link\">",
"      Left bundle branch block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26858?source=related_link\">",
"      Monomorphic ventricular tachycardia in the absence of apparent structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38422?source=related_link\">",
"      Myocardial action potential and action of antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7514?source=related_link\">",
"      Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=related_link\">",
"      Pulmonary artery catheterization: Indications and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/36/10823?source=related_link\">",
"      Rationale for and mechanisms of benefit of cardiac resynchronization therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/62/998?source=related_link\">",
"      Second degree atrioventricular block: Mobitz type II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/8/43144?source=related_link\">",
"      Sustained monomorphic ventricular tachycardia: Diagnosis and evaluation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_6_10345="Carbon monoxide poisoning";
var content_f10_6_10345=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Carbon monoxide poisoning",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/6/10345/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/6/10345/contributors\">",
"     Peter F Clardy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/6/10345/contributors\">",
"     Scott Manaker, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/6/10345/contributors\">",
"     Holly Perry, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/6/10345/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/6/10345/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/6/10345/contributors\">",
"     Michele Burns Ewald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/6/10345/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/6/10345/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/6/10345/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carbon monoxide (CO) is an odorless, tasteless, colorless, nonirritating gas formed by hydrocarbon combustion. The atmospheric concentration of CO is generally below 0.001 percent, but it may be higher in urban areas or enclosed environments. CO binds to hemoglobin with much greater affinity than oxygen, forming carboxyhemoglobin (COHb) and resulting in impaired oxygen transport and utilization. CO can also precipitate an inflammatory cascade that results in CNS lipid peroxidation and delayed neurologic sequelae.",
"   </p>",
"   <p>",
"    CO poisoning will be reviewed here. A summary table to facilitate emergent management is provided (",
"    <a class=\"graphic graphic_table graphicRef60672 \" href=\"UTD.htm?38/41/39580\">",
"     table 1",
"    </a>",
"    ). Related topics including smoke inhalation and hyperbaric oxygen therapy are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22790?source=see_link\">",
"     \"Smoke inhalation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5448?source=see_link\">",
"     \"Hyperbaric oxygen therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carbon monoxide (CO) poisoning is responsible for up to 40,000 emergency department visits and 5000 to 6000 deaths per year, making it one of the leading causes of poisoning death in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Inadvertent CO poisoning likely causes around 500 deaths annually; the number of intentional CO poisonings is perhaps 10 times higher [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/1,4,5\">",
"     1,4,5",
"    </a>",
"    ]. The overall case-fatality rate for CO poisoning ranges from 0 to 31 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/3,6,7\">",
"     3,6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unlike intentional poisoning, unintended poisoning demonstrates both seasonal and regional variation, and it is most common during the winter months in cold climates [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/5\">",
"     5",
"    </a>",
"    ]. Morbidity, which is primarily related to late neurocognitive impairment, persists beyond initial stabilization in up to 40 percent of victims [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/3,6\">",
"     3,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Smoke inhalation is responsible for most inadvertent cases of CO poisoning. Other potential sources of CO include poorly functioning heating systems, improperly vented fuel-burning devices (eg, kerosene heaters, charcoal grills, camping stoves [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/8\">",
"     8",
"    </a>",
"    ], gasoline-powered electrical generators [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/9\">",
"     9",
"    </a>",
"    ]), and motor vehicles operating in poorly ventilated areas (eg, ice rinks, warehouses, parking garages). CO poisonings following open air exposure to motorboat exhaust have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/10\">",
"     10",
"    </a>",
"    ]. In addition, underground electrical cable fires produce large amounts of CO, which can seep into adjacent buildings and homes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/11\">",
"     11",
"    </a>",
"    ]. An increase in carbon monoxide exposures has been reported to occur in the immediate aftermath of hurricanes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/9,12,13\">",
"     9,12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Methylene chloride (dichloromethane) is an industrial solvent and a component of paint remover. Inhaled or ingested methylene chloride is metabolized to CO by the liver, causing CO toxicity in the absence of ambient CO [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/1,14\">",
"     1,14",
"    </a>",
"    ]. The US Occupational Safety and Health Administration lowered the workplace exposure limit for methylene chloride from 500 to 25 parts per million (ppm) based on concerns over the chronic effects of carboxyhemoglobinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/13/14553?source=see_link\">",
"     \"Overview of occupational and environmental health\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carbon monoxide (CO) diffuses rapidly across the pulmonary capillary membrane and binds to the iron moiety of heme (and other porphyrins) with approximately 240 times the affinity of oxygen. The degree of carboxyhemoglobinemia (COHb) is a function of the relative amounts of CO and oxygen in the environment, duration of exposure, and minute ventilation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31430?source=see_link\">",
"     \"Oxygen delivery and consumption\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonsmokers may have up to 3 percent carboxyhemoglobin at baseline; smokers may have levels of 10 to 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/1\">",
"     1",
"    </a>",
"    ]. Severe chronic obstructive pulmonary disease can cause a modest but significant elevation in carboxyhemoglobin levels, even among patients without exposure to tobacco smoke. The mechanism and clinical significance of this finding is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once CO binds to the heme moiety of hemoglobin, an allosteric change occurs that greatly diminishes the ability of the other three oxygen binding sites to off-load oxygen to peripheral tissues. This results in a deformation and leftward shift of the oxyhemoglobin dissociation curve, and compounds the impairment in tissue oxygen delivery (",
"    <a class=\"graphic graphic_figure graphicRef50058 \" href=\"UTD.htm?27/34/28207\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    CO also interferes with peripheral oxygen utilization. Approximately 10 to 15 percent of CO is extravascular and bound to molecules such as myoglobin, cytochromes, and NADPH reductase, resulting in impairment of oxidative phosphorylation at the mitochondrial level [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/6,17\">",
"     6,17",
"    </a>",
"    ]. The half-life of CO bound to these molecules is longer than that of COHb. The importance of these non-hemoglobin-mediated effects has been best documented in the heart, where mitochondrial dysfunction due to CO can produce myocardial stunning despite adequate oxygen delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CO also interferes with peripheral oxygen utilization by inactivating cytochrome oxidase in a manner similar to, but clinically less important than, cyanide. CO and cyanide poisoning can occur simultaneously in patients following smoke inhalation, and their combined effects on oxygen transport and utilization appear to be synergistic [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22790?source=see_link&amp;anchor=H19#H19\">",
"     \"Smoke inhalation\", section on 'Cyanide poisoning'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effects of CO on oxygen delivery and utilization, however, cannot account for the delayed neurologic sequelae (DNS) that may occur after CO poisoning. The mechanism of DNS is incompletely understood, but it probably involves lipid peroxidation by toxic oxygen species generated by xanthine oxidase. Xanthine oxidase is produced in situ from xanthine dehydrogenase via enzymes released by white blood cells that adhere to damaged endothelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/21-25\">",
"     21-25",
"    </a>",
"    ]. During recovery from CO exposure, events analogous to ischemia-reperfusion injury and exposure to hyperoxia may exacerbate the initial oxidative damage [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/2,26\">",
"     2,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     KINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carbon monoxide (CO) is rapidly absorbed across the pulmonary endothelium. Elimination is dependent upon the degree of oxygenation and, to a lesser extent, minute ventilation. The half-life of CO while a patient is breathing room air is approximately 300 minutes, while breathing high-flow oxygen via a nonrebreathing face mask is about 90 minutes and with 100 percent hyperbaric oxygen is approximately 30 minutes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Symptoms and signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical findings of carbon monoxide (CO) poisoning are highly variable and largely nonspecific [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef60672 \" href=\"UTD.htm?38/41/39580\">",
"     table 1",
"    </a>",
"    ). Moderately or mildly CO-intoxicated patients often present with constitutional symptoms, including headache (the most common presenting symptom), malaise, nausea, and dizziness, and may be misdiagnosed with acute viral syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/26\">",
"     26",
"    </a>",
"    ]. In addition to current symptoms, the clinician should specifically inquire (of the patient",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    witnesses) about loss of consciousness.",
"   </p>",
"   <p>",
"    In the absence of concurrent trauma or burns, physical findings in CO poisoning are usually confined to alterations in mental status, so a careful neurologic examination is crucial. Patients may manifest symptoms ranging from mild confusion to coma. Specific cognitive testing, such as the Carbon Monoxide Neuropsychological Screening Battery, is usually not used in the acute setting and, in any event, is not universally endorsed due to its inability to discriminate between the effects of CO and those of other intoxicants [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/1,24\">",
"     1,24",
"    </a>",
"    ]. Although some textbooks describe a \"cherry red\" appearance of the lips and skin as indicative of CO poisoning, this is an insensitive sign [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Severe CO toxicity can produce neurologic symptoms such as seizures, syncope, or coma, and also cardiovascular and metabolic manifestations such as myocardial ischemia, ventricular arrhythmias, pulmonary edema, and profound lactic acidosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Myocardial injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute myocardial injury is common among CO-poisoned patients and is associated with increased long-term mortality. A retrospective study of 230 patients with moderate or severe CO poisoning referred to a specialized center found evidence of myocardial ischemia (characteristic electrocardiographic changes or elevated serum cardiac biomarkers) in one-third of all cases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long-term follow-up (median 7.6 years) of this cohort noted a mortality rate of 24 percent among patients who sustained acute myocardial injury [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/30\">",
"     30",
"    </a>",
"    ]. Mortality among patients with myocardial injury was more than twice that of poisoned patients without evidence of such injury, and was estimated to be triple that expected for a comparable unpoisoned cohort.",
"   </p>",
"   <p>",
"    This study population was young (mean age 47 years) and had a low incidence of established cardiac disease or cardiac risk factors, other than smoking. It is probable that the incidence of myocardial ischemia among CO-poisoned patients with established cardiac disease is even higher.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Delayed neuropsychiatric syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;In up to 40 percent of patients with significant CO exposure, a syndrome of delayed neurologic sequelae (DNS) can arise 3 to 240 days after apparent recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. Characterized by variable degrees of cognitive deficits, personality changes, movement disorders, and focal neurologic deficits, DNS generally occur within 20 days of CO poisoning, and deficits may persist for a year or longer.",
"   </p>",
"   <p>",
"    The development of DNS correlates poorly with COHb levels, although the majority of cases are associated with loss of consciousness during acute intoxication [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/1,6,35\">",
"     1,6,35",
"    </a>",
"    ]. The incidence and severity of DNS have become increasingly important clinical end points in studies of treatment for CO poisoning. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Hyperbaric oxygen'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H5571168\">",
"     'Hyperbaric oxygen and delayed neuropsychiatric syndrome (DNS)'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute carbon monoxide (CO) poisoning is usually suspected on the basis of a suggestive history, while the diagnosis of chronic CO intoxication is notoriously difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/1,28\">",
"     1,28",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef60672 \" href=\"UTD.htm?38/41/39580\">",
"     table 1",
"    </a>",
"    ). Standard pulse oximetry (Sp02)",
"    <strong>",
"     CANNOT",
"    </strong>",
"    screen for CO exposure, as it does not differentiate carboxyhemoglobin from oxyhemoglobin (",
"    <a class=\"graphic graphic_figure graphicRef65554 \" href=\"UTD.htm?31/38/32365\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Eight-wavelength pulse oximeters capable of measuring carboxyhemoglobin and methemoglobin are being developed, but need further study [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9736?source=see_link&amp;anchor=H8#H8\">",
"     \"Pulse oximetry\", section on 'Abnormal hemoglobins'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of CO poisoning is based upon a compatible history and physical examination in conjunction with an elevated carboxyhemoglobin level measured by cooximetry of an arterial blood gas sample. Nonsmokers may have up to 3 percent carboxyhemoglobin at baseline; smokers may have levels of 10 to 15 percent. Levels above these respective values are consistent with CO poisoning.",
"   </p>",
"   <p>",
"    Carboxyhemoglobin levels correlate imprecisely with the degree of poisoning and are not predictive of delayed neurologic sequelae (DNS). Venous samples may be used to determine the carboxyhemoglobin level, but they are less accurate in quantifying the associated acidosis. The main uses of venous carboxyhemoglobin are in screening large numbers of potential CO victims in a disaster situation, or in monitoring the change in carboxyhemoglobin level over time during treatment.",
"   </p>",
"   <p>",
"    Case reports suggest that treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/46/43749?source=see_link\">",
"     hydroxocobalamin",
"    </a>",
"    (as might be performed for presumed cyanide exposure from smoke inhalation) can interfere with the measurement of carboxyhemoglobin leading to falsely low results [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/40\">",
"     40",
"    </a>",
"    ]. In patients with possible cyanide exposure (eg, brought to the hospital from a fire), clinicians should ask whether hydroxocobalamin was given.",
"   </p>",
"   <p>",
"    Noninvasive pulse cooximeters capable of photo spectroscopic measurements of carboxyhemoglobin are in development [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/41\">",
"     41",
"    </a>",
"    ]. However, preliminary observational studies question their accuracy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Until well-performed trials demonstrate that these devices provide consistently accurate measurements, we cannot recommend their routine clinical use.",
"   </p>",
"   <p>",
"    Blood PO2 measurements tend to be normal because PO2 reflects O2 dissolved in blood, and this process is not affected by CO. In contrast, hemoglobin-bound O2 (which normally comprises 98 percent of arterial O2 content) is profoundly reduced in the presence of COHb. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31430?source=see_link\">",
"     \"Oxygen delivery and consumption\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once the diagnosis of CO intoxication is confirmed, we recommend obtaining an electrocardiogram (ECG); cardiac biomarker evaluation is warranted in patients with ECG evidence of ischemia or a history of cardiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Computed tomography (CT) of the head is usually helpful only to rule out other causes of neurologic decompensation. Hemorrhagic infarction of the globus pallidus and, less frequently, the deep white matter have been reported following acute intoxication, but they are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/44\">",
"     44",
"    </a>",
"    ]. Imaging studies, including CT, magnetic resonance imaging (MRI), and positron-emission tomography (PET), suggest that abnormalities in the globus pallidus and deep white matter may be noted in the setting of DNS [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/32,45-48\">",
"     32,45-48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Initial treament and disposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carbon monoxide (CO) is removed almost exclusively via the pulmonary circulation through competitive binding of hemoglobin by oxygen. The half-life of carboxyhemoglobin (COHb) in a patient breathing room air is approximately 300 minutes; this decreases to 90 minutes with high-flow oxygen via a nonrebreathing mask. Thus, the most important interventions in the management of a CO-poisoned patient are prompt removal from the source of CO and institution of high-flow oxygen by face mask. A summary table to facilitate emergent management is provided (",
"    <a class=\"graphic graphic_table graphicRef60672 \" href=\"UTD.htm?38/41/39580\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Comatose patients, or those with severely impaired mental status, should be intubated without delay and mechanically ventilated using 100 percent oxygen. For patients suffering from CO poisoning after smoke inhalation, it is important to consider concomitant cyanide toxicity, which can further impair tissue oxygen utilization and exacerbate cellular hypoxia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/17,19\">",
"     17,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22790?source=see_link\">",
"     \"Smoke inhalation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/18/7466?source=see_link\">",
"     \"Cyanide poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many patients can be managed in the emergency department, as most symptoms resolve with high-flow oxygen. Patients whose symptoms do not resolve, who demonstrate electrocardiogram (ECG) or laboratory evidence of severe poisoning, or who have other medical or social cause for concern should be hospitalized. Psychiatric assessment and determination of suicidality are crucial following intentional CO poisoning. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10377?source=see_link\">",
"     \"Suicidal ideation and behavior in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many acute care hospitals lack the ability to measure carboxyhemoglobin concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/49\">",
"     49",
"    </a>",
"    ]. Patients suspected of CO poisoning who are treated in hospitals without on-site cooximetry should be treated with 100 percent oxygen via nonrebreathing face mask. Clinicians at such hospitals should strongly consider the immediate transfer of patients at high risk for adverse outcomes (specifically those with acidemia, ischemic ECG changes, persistent chest pain, or altered mental status) to facilities capable of providing hyperbaric oxygen therapy.",
"   </p>",
"   <p>",
"    Source identification is critical in cases of unintentional poisoning, in order to limit the risk to others. Local fire departments or other emergency management personnel can assist with an assessment of CO level in the suspected environment and removal of victims [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Hyperbaric oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperbaric oxygen therapy (HBO) involves exposing patients to 100 percent oxygen under supra-atmospheric conditions. This results in a decrease in the half-life of carboxyhemoglobin (COHb), from approximately 90 minutes on 100 percent normobaric oxygen to approximately 30 minutes during HBO. The amount of oxygen dissolved in the blood also rises from approximately 0.3 to 6.0 mL per dL, which substantially increases the delivery of non-hemoglobin-bound oxygen to the tissues. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5448?source=see_link\">",
"     \"Hyperbaric oxygen therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the uncertainty in identifying patients who will benefit from HBO treatment, a broad set of recommendations has been established for therapy of CO-intoxicated patients (",
"    <a class=\"graphic graphic_algorithm graphicRef59259 \" href=\"UTD.htm?30/19/31038\">",
"     algorithm 1",
"    </a>",
"    ). In addition to a COHb level above 25 percent (see below), criteria for treatment with HBO include: evidence of ongoing end-organ ischemia (eg, profound metabolic acidosis (pH &lt;7.1), myocardial ischemia), loss of consciousness, or in pregnant women a COHb &gt;20 percent or evidence of fetal distress [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/1,2,28,50\">",
"     1,2,28,50",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'HBO during pregnancy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The COHb level at which HBO should be performed, independent of clinical status, is controversial. Many medical toxicologists routinely recommend HBO when the carboxyhemoglobin level is greater than 25 percent, whereas some societies use 40 percent as the appropriate threshold. There is no clear basis in the medical literature for choosing one level over the other. We routinely advocate HBO in patients with a COHb level greater than 25 percent, but recognize other clinicians may disagree based on their interpretation of existing studies.",
"   </p>",
"   <p>",
"    The potential benefit of HBO is greater the more rapidly treatment is provided. Ideally, HBO should be initiated within six hours. Benefit for patients treated more than 12 hours after their CO exposure is unproven. Despite some positive studies, the use of HBO in mild to moderate CO poisoning is not routine, and we do not recommend HBO for patients other than those in the high-risk groups listed above. All patients selected to receive HBO should have at least one treatment at 2.5 to 3.0 atm as soon as possible to reverse the acute effects of CO intoxication, with possible additional therapy directed toward limitation or prevention of delayed neuropsychiatric syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/1,19,29,51\">",
"     1,19,29,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The other indications, complications, and technique of HBO are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5448?source=see_link\">",
"     \"Hyperbaric oxygen therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 1500 patients with CO poisoning are treated with HBO in the United States every year [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/34\">",
"     34",
"    </a>",
"    ]. A major impediment to the wider application of HBO in the management of CO poisoning is the limited availability of hyperbaric chambers. In the United States, approximately 250 hyperbaric facilities offer either single occupant (\"monoplace\") or multiple occupant (\"multiplace\") chambers. Information regarding the location of hyperbaric facilities can be accessed through the Undersea and Hyperbaric Medical Society website (",
"    <a class=\"external\" href=\"file://www.uhms.org/\">",
"     www.uhms.org",
"    </a>",
"    ) or via the Divers Alert Network Emergency Hotline (1-919-684-8111) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5571168\">",
"    <span class=\"h2\">",
"     Hyperbaric oxygen and delayed neuropsychiatric syndrome (DNS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperbaric oxygen therapy (HBO) may be beneficial in preventing the late neurocognitive deficits associated with severe CO intoxication. If HBO is used, the available literature suggests that benefit is greatest if treatment begins as early as possible, ideally within six hours [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. The indications for HBO are discussed above. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Hyperbaric oxygen'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The quality and results of clinical trials designed to assess the efficacy of HBO in reducing the severity of DNS have varied widely [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/3,31,54-60\">",
"     3,31,54-60",
"    </a>",
"    ]. Of several such studies, the two most important, double-blinded trials that included all patients regardless of poisoning severity came to contradictory conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/54,58\">",
"     54,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The first was a single-center, controlled trial that randomly assigned 152 patients within 24 hours of presentation to hyperbaric or normobaric oxygen therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/54\">",
"     54",
"    </a>",
"    ]. Treatment was administered during three sessions in a hyperbaric chamber, effectively blinding the therapy a patient was receiving. Six weeks after presentation, cognitive sequelae were more common in the group treated with normobaric oxygen (46 versus 25 percent). This advantage of hyperbaric therapy in terms of neurologic performance was maintained at six months and one year following initial presentation.",
"   </p>",
"   <p>",
"    Discordant findings were noted in a randomized trial of 191 patients referred to a tertiary center with CO poisoning during a two-year period, which failed to document benefit for patients who received HBO [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/56\">",
"     56",
"    </a>",
"    ]. Rather, delayed neurologic sequelae and poor performance on neuropsychiatric tests after one month were significantly more common among HBO-treated patients.",
"   </p>",
"   <p>",
"    A subsequent dual-armed randomized controlled trial assessed the effect of HBO among patients with transient loss of consciousness or coma at the time of presentation following domestic CO poisoning. Among the patients with transient loss of consciousness (but without coma at presentation), the use of a single session of HBO showed no benefit in the rate of complete neurocognitive recovery at one month compared with 100 percent oxygen therapy (58 versus 61 percent; OR 0.90, 95% CI 0.47-1.71). For patients presenting with coma, those undergoing two sessions of HBO experienced a significantly lower rate of recovery at one month compared with those treated with a single session of HBO (47 versus 68 percent; OR 0.42, 95% CI 0.23-0.79) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/59\">",
"     59",
"    </a>",
"    ]. This trial was stopped early based on an interim analysis suggesting harm associated with HBO among patients presenting with coma. Limitations of this trial include uncertainty surrounding the presence or absence of coma at the time of presentation (which was based upon bystander observation), the relatively large number of patients lost to follow-up, and the use of 2 rather than 3 atmospheres of pressure for HBO therapy.",
"   </p>",
"   <p>",
"    A systematic review of the HBO literature noted methodological flaws in all of the studies described above [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/60\">",
"     60",
"    </a>",
"    ]. Limitations of the positive trial included a disparity in the severity of toxicity between patients randomized to normobaric oxygen therapy (NBO), (mean CO exposure of 22 hours), and patients treated with HBO, (mean CO exposure of 13 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/54\">",
"     54",
"    </a>",
"    ]. Negative trials suffered from incomplete follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/56,59\">",
"     56,59",
"    </a>",
"    ], use of lower pressure (&lt;2.5 atm) HBO [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/59\">",
"     59",
"    </a>",
"    ], delays in treatment (mean time to HBO therapy over six hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/56\">",
"     56",
"    </a>",
"    ], and use of continuous NBO treatment for three days in patients not receiving HBO [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/56\">",
"     56",
"    </a>",
"    ]. Such methodological problems make it difficult to draw conclusions about the ability of HBO to decrease DNS following CO poisoning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     HBO during pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of pregnancy on the decision to initiate HBO is based on the greater affinity and longer half-life of CO bound to fetal hemoglobin, the inability to substantially increase placental perfusion, and the direct effects of hypoxemia and acidosis on the fetus. A prospective, multicenter study of fetal outcome following accidental CO poisoning found no physical or neurobehavioral deficits in 31 infants who were exposed to CO in utero when their mothers suffered mild to moderate CO poisoning [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/61\">",
"     61",
"    </a>",
"    ]. Severe maternal poisoning, however, resulted in adverse outcomes in three of five patients treated with normobaric oxygen alone; HBO was used in two other cases, and those children did not demonstrate evidence of prenatal injury. Exposure to HBO does not seem to adversely affect the fetus, but the published experience is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is limited information on the characteristics of the fetal heart rate tracing of pregnant women with carbon monoxide poisoning in the third trimester. In the few cases with detailed reports, the initial tracing showed baseline fetal tachycardia of 160 to 190 beats per minute in three of four fetuses, and all four had minimal variability with no accelerations or decelerations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. After 60 to 90 minutes of maternal HBO therapy, all of the tracings became normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Isocapnic hyperpnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;The elimination half-life of COHb is, in part, a function of minute ventilation. Isocapnic hyperpnea is a technique by which an intubated patient is hyperventilated with a normobaric mixture of oxygen and a small amount of CO2, maintaining a PaCO2 of approximately 40 mmHg despite a sixfold increase in minute ventilation. Application of this technique in an animal model more than doubled the rate of CO elimination compared with conventional ventilation with 100 percent oxygen [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/65\">",
"     65",
"    </a>",
"    ]. Furthermore, the technology required for isocapnic hyperpnea is much less expensive and cumbersome than HBO. Adding CO2 to the respiratory circuit",
"    <strong>",
"     MUST",
"    </strong>",
"    be accompanied by assisted hyperventilation or respiratory acidosis may occur, compounding the metabolic acidosis produced by carboxyhemoglobin.",
"   </p>",
"   <p>",
"    A conceptually similar approach has been tested experimentally in nonintubated patients. One study randomly assigned seven patients with COHb levels of 10 to 12 percent to receive either 100 percent oxygen via face mask or FiO2 &gt;95 percent with 4.5 to 4.8 percent CO2, in order to maintain normocapnia with a minute ventilation two to six times baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/66\">",
"     66",
"    </a>",
"    ]. The half-life of COHb was significantly reduced by the isocapnic hyperpnea approach (31 versus 78 minutes). To date, there are no clinical trials showing that isocapnic hyperpnea reduces the risk of delayed neurologic sequelae and larger trials are needed before this approach can be endorsed for all patients; however, the relative simplicity and low cost of this technique suggest that it might have a role in the early management of suspected CO poisoning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PEDIATRIC CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In young children, signs of carbon monoxide poisoning may be more subtle and nonspecific than those in adults. Infants and toddlers may present with complaints such as fussiness and feeding difficulty as the sole manifestation of carbon monoxide poisoning [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/67\">",
"     67",
"    </a>",
"    ]. Because of their higher oxygen utilization and higher minute ventilation, young children may develop signs and symptoms of carbon monoxide poisoning before older children and adults who experience the same exposure (eg, family members living in a house with a faulty furnace).",
"   </p>",
"   <p>",
"    In contrast, older children have symptoms similar to adults as they are able to verbalize feelings of headache and nausea. The incidence of delayed neuropsychological sequelae in the pediatric population falls between 3 and 17 percent (lower than that reported in adults) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/68-70\">",
"     68-70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patient age does not alter the management of carbon monoxide poisoning. Although theoretical reasons for both more or less aggressive treatment in young children exist, there are no human studies upon which to base a recommendation and treatment centers generally do not alter their approach to therapy based upon age.",
"   </p>",
"   <p>",
"    When hyperbaric oxygen therapy (HBO) is administered to young children, specific concerns must be addressed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Myringotomy should be performed in children with active otitis media who are younger than five years or who are unable to equalize their middle ear pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?10/6/10345/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      It may be helpful to allow a family member to accompany a frightened child into the chamber.",
"     </li>",
"     <li>",
"      When HBO is administered to an infant, care must be taken to keep the infant warm: Children in this age group easily become hypothermic.",
"     </li>",
"     <li>",
"      Congenital abnormalities must also be taken in account:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A chest radiograph should be obtained to detect congenital anomalies such as lobar emphysema which could lead to a pneumothorax.",
"     </li>",
"     <li>",
"      Patients with unpalliated ductal dependent cardiac lesions should undergo HBO with caution as oxygen may precipitate duct closure. In most cases, such patients are poor candidates for HBO. Consultation with a pediatric cardiologist is prudent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32783068\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of patients who sustain hypoxic-ischemic brain injury from any cause, including severe CO poisoning, is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19337?source=see_link&amp;anchor=H10#H10\">",
"     \"Hypoxic-ischemic brain injury: Evaluation and prognosis\", section on 'Prognosis based on clinical findings'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Home carbon monoxide (CO) monitors equipped with alarms are relatively inexpensive, widely available, and potentially life-saving. The US Consumer Product Safety Commission (CPSC) recommends that every home have a CO monitor equipped with an alarm; further information is available online",
"    <a class=\"external\" href=\"file://www.cpsc.gov/\">",
"     www.cpsc.gov",
"    </a>",
"    or via their hotline (1-800-638-2772).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13112121\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/44/17089?source=see_link\">",
"       \"Patient information: Carbon monoxide (CO) poisoning (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carbon monoxide (CO) poisoning is common, potentially fatal, and probably underdiagnosed because of its nonspecific clinical presentation. CO has profound effects on oxygen transport and, to a lesser degree, peripheral oxygen utilization. In addition to the extended summary below, a brief table to facilitate emergent management is provided (",
"    <a class=\"graphic graphic_table graphicRef60672 \" href=\"UTD.htm?38/41/39580\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CO poisoning is most common during winter in cold climates, but it may occur in all seasons and environments. Smoke inhalation is responsible for most unintentional cases. Other potential sources of CO include poorly functioning heating systems, improperly vented fuel-burning devices (eg, kerosene heaters, charcoal grills, camping stoves, gasoline-powered electrical generators), and motor vehicles operating in poorly ventilated areas. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CO diffuses rapidly across the pulmonary capillary membrane and binds to the iron moiety of heme with approximately 240 times the affinity of oxygen. The degree of carboxyhemoglobinemia (COHb) is a function of the relative amounts of CO and oxygen in the environment, duration of exposure, and minute ventilation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical findings of CO poisoning are highly variable and largely nonspecific. Mild to moderate CO-intoxicated patients often present with constitutional symptoms, including headache (most common), malaise, nausea, and dizziness, and may be misdiagnosed with acute viral syndromes. In the absence of concurrent trauma or burns, physical findings in CO poisoning are usually confined to alterations in mental status, ranging from mild confusion to seizures and coma. A careful neurologic examination is crucial. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cardiac ischemia can occur. Once the diagnosis of CO intoxication is confirmed, we recommend obtaining an electrocardiogram (ECG); cardiac biomarker evaluation is warranted in patients with ECG evidence of ischemia, symptoms suggestive of ischemia, age greater than 65 years, or a history of cardiac disease or cardiac risk factors. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of CO poisoning is based upon a compatible history and physical examination in conjunction with an elevated carboxyhemoglobin level. Diagnosis requires quantification by cooximetry of a blood gas sample; standard pulse oximetry (SP02) is unable to distinguish between oxyhemoglobin and COHb. Blood PO2 measurements tend to be normal because PO2 reflects O2 dissolved in blood, and this process is not affected by CO. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Continual assessment and standard interventions to secure the airway, breathing, and circulation of the patient poisoned with CO are of paramount importance. We recommend that all comatose patients and those with severely impaired mental status be intubated without delay and mechanically ventilated (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most important interventions in the management of a CO-poisoned patient are prompt removal from the source of CO and institution of 100 percent oxygen by nonrebreathing face mask or endotracheal tube. We recommend initial treatment with 100 percent normobaric oxygen for all suspected victims of CO poisoning, regardless of pulse oximetry or arterial PO2 (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who have severe intoxication, there is controversy surrounding the ability of hyperbaric oxygen therapy (HBO) to decrease the incidence and severity of delayed neurocognitive deficits following CO poisoning. Expert guidelines regarding the judicious use of hyperbaric oxygen have been published (",
"      <a class=\"graphic graphic_algorithm graphicRef59259 \" href=\"UTD.htm?30/19/31038\">",
"       algorithm 1",
"      </a>",
"      ). We suggest treatment with HBO in the following circumstances (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      CO level &gt;25 percent",
"     </li>",
"     <li>",
"      CO level &gt;20 percent in pregnant patient",
"     </li>",
"     <li>",
"      Loss of consciousness",
"     </li>",
"     <li>",
"      Severe metabolic acidosis (pH &lt;7.1)",
"     </li>",
"     <li>",
"      Evidence of end-organ ischemia (eg, ECG changes, chest pain, altered mental status) (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Management'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many patients with mild symptoms from an unintentional poisoning can be managed in an emergency department and safely discharged. Patients whose symptoms do not resolve, who demonstrate ECG or laboratory evidence of severe poisoning, or who have other medical or social cause for concern should be hospitalized. Psychiatric evaluation must be obtained for all patients with self-inflicted CO poisoning. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Determination of the mechanism of exposure is critical in cases of unintentional poisoning in order to limit the risk to others. Local fire departments can assist with an assessment of CO level and removal of victims in the suspected environment. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/1\">",
"      Ernst A, Zibrak JD. Carbon monoxide poisoning. N Engl J Med 1998; 339:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/2\">",
"      Weaver LK. Carbon monoxide poisoning. Crit Care Clin 1999; 15:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/3\">",
"      Tibbles PM, Perrotta PL. Treatment of carbon monoxide poisoning: a critical review of human outcome studies comparing normobaric oxygen with hyperbaric oxygen. Ann Emerg Med 1994; 24:269.",
"     </a>",
"    </li>",
"    <li>",
"     www.cdc.gov/nceh/airpollution/carbonmonoxide/cofaq.htm (Accessed on August 09, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/5\">",
"      Centers for Disease Control and Prevention (CDC). Unintentional non-fire-related carbon monoxide exposures--United States, 2001-2003. MMWR Morb Mortal Wkly Rep 2005; 54:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/6\">",
"      Hardy KR, Thom SR. Pathophysiology and treatment of carbon monoxide poisoning. J Toxicol Clin Toxicol 1994; 32:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/7\">",
"      Hampson NB, Hauff NM. Risk factors for short-term mortality from carbon monoxide poisoning treated with hyperbaric oxygen. Crit Care Med 2008; 36:2523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/8\">",
"      Thomassen &Oslash;, Bratteb&oslash; G, Rostrup M. Carbon monoxide poisoning while using a small cooking stove in a tent. Am J Emerg Med 2004; 22:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/9\">",
"      Centers for Disease Control and Prevention (CDC). Carbon monoxide poisoning from hurricane-associated use of portable generators--Florida, 2004. MMWR Morb Mortal Wkly Rep 2005; 54:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/10\">",
"      Centers for Disease Control and Prevention (CDC). Carbon monoxide poisonings resulting from open air exposures to operating motorboats--Lake Havasu City, Arizona, 2003. MMWR Morb Mortal Wkly Rep 2004; 53:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/11\">",
"      Centers for Disease Control and Prevention (CDC). Carbon monoxide releases and poisonings attributed to underground utility cable fires--New York, January 2000-June 2004. MMWR Morb Mortal Wkly Rep 2004; 53:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/12\">",
"      Centers for Disease Control and Prevention (CDC). Monitoring poison control center data to detect health hazards during hurricane season--Florida, 2003-2005. MMWR Morb Mortal Wkly Rep 2006; 55:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/13\">",
"      Cukor J, Restuccia M. Carbon monoxide poisoning during natural disasters: the Hurricane Rita experience. J Emerg Med 2007; 33:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/14\">",
"      Chang YL, Yang CC, Deng JF, et al. Diverse manifestations of oral methylene chloride poisoning: report of 6 cases. J Toxicol Clin Toxicol 1999; 37:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/15\">",
"      Amsel J, Soden KJ, Sielken RL Jr, Valdez-Flora C. Observed versus predicted carboxyhemoglobin levels in cellulose triacetate workers exposed to methylene chloride. Am J Ind Med 2001; 40:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/16\">",
"      Yasuda H, Yamaya M, Nakayama K, et al. Increased arterial carboxyhemoglobin concentrations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 171:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/17\">",
"      Vogel SN, Sultan TR, Ten Eyck RP. Cyanide poisoning. Clin Toxicol 1981; 18:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/18\">",
"      Tritapepe L, Macchiarelli G, Rocco M, et al. Functional and ultrastructural evidence of myocardial stunning after acute carbon monoxide poisoning. Crit Care Med 1998; 26:797.",
"     </a>",
"    </li>",
"    <li>",
"     Ellenhorn's Medical Toxicology: Diagnosis and Treatment of Human Poisoning, 2nd ed, Ellenhorn MJ, Schonwald S, Ordog G, Wasserberger J (Eds), Williams &amp; Wilkins, Baltimore 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/20\">",
"      Norris JC, Moore SJ, Hume AS. Synergistic lethality induced by the combination of carbon monoxide and cyanide. Toxicology 1986; 40:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/21\">",
"      Thom SR, Bhopale VM, Fisher D, et al. Delayed neuropathology after carbon monoxide poisoning is immune-mediated. Proc Natl Acad Sci U S A 2004; 101:13660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/22\">",
"      Goldbaum LR, Ramirez RG, Absalon KB. What is the mechanism of carbon monoxide toxicity? Aviat Space Environ Med 1975; 46:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/23\">",
"      Zhang J, Piantadosi CA. Mitochondrial oxidative stress after carbon monoxide hypoxia in the rat brain. J Clin Invest 1992; 90:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/24\">",
"      Thom SR. Carbon monoxide-mediated brain lipid peroxidation in the rat. J Appl Physiol 1990; 68:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/25\">",
"      Thom SR, Xu YA, Ischiropoulos H. Vascular endothelial cells generate peroxynitrite in response to carbon monoxide exposure. Chem Res Toxicol 1997; 10:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/26\">",
"      Tomaszewski C. Carbon monoxide poisoning. Early awareness and intervention can save lives. Postgrad Med 1999; 105:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/27\">",
"      Harper A, Croft-Baker J. Carbon monoxide poisoning: undetected by both patients and their doctors. Age Ageing 2004; 33:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/28\">",
"      Kao LW, Na&ntilde;agas KA. Carbon monoxide poisoning. Emerg Med Clin North Am 2004; 22:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/29\">",
"      Satran D, Henry CR, Adkinson C, et al. Cardiovascular manifestations of moderate to severe carbon monoxide poisoning. J Am Coll Cardiol 2005; 45:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/30\">",
"      Henry CR, Satran D, Lindgren B, et al. Myocardial injury and long-term mortality following moderate to severe carbon monoxide poisoning. JAMA 2006; 295:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/31\">",
"      Thom SR, Taber RL, Mendiguren II, et al. Delayed neuropsychologic sequelae after carbon monoxide poisoning: prevention by treatment with hyperbaric oxygen. Ann Emerg Med 1995; 25:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/32\">",
"      Choi IS. Delayed neurologic sequelae in carbon monoxide intoxication. Arch Neurol 1983; 40:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/33\">",
"      Kwon OY, Chung SP, Ha YR, et al. Delayed postanoxic encephalopathy after carbon monoxide poisoning. Emerg Med J 2004; 21:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/34\">",
"      Hampson NB, Little CE. Hyperbaric treatment of patients with carbon monoxide poisoning in the United States. Undersea Hyperb Med 2005; 32:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/35\">",
"      Seger D, Welch L. Carbon monoxide controversies: neuropsychologic testing, mechanism of toxicity, and hyperbaric oxygen. Ann Emerg Med 1994; 24:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/36\">",
"      Bozeman WP, Myers RA, Barish RA. Confirmation of the pulse oximetry gap in carbon monoxide poisoning. Ann Emerg Med 1997; 30:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/37\">",
"      Tremper KK, Barker SJ. Pulse oximetry. Anesthesiology 1989; 70:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/38\">",
"      Barker SJ, Curry J, Redford D, Morgan S. Measurement of carboxyhemoglobin and methemoglobin by pulse oximetry: a human volunteer study. Anesthesiology 2006; 105:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/39\">",
"      Roth D, Herkner H, Schreiber W, et al. Accuracy of noninvasive multiwave pulse oximetry compared with carboxyhemoglobin from blood gas analysis in unselected emergency department patients. Ann Emerg Med 2011; 58:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/40\">",
"      Livshits Z, Lugassy DM, Shawn LK, Hoffman RS. Falsely low carboxyhemoglobin level after hydroxocobalamin therapy. N Engl J Med 2012; 367:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/41\">",
"      Plante T, Harris D, Savitt J, et al. Carboxyhemoglobin monitored by bedside continuous CO-oximetry. J Trauma 2007; 63:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/42\">",
"      O'Malley GF. Non-invasive carbon monoxide measurement is not accurate. Ann Emerg Med 2006; 48:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/43\">",
"      Touger M, Birnbaum A, Wang J, et al. Performance of the RAD-57 pulse CO-oximeter compared with standard laboratory carboxyhemoglobin measurement. Ann Emerg Med 2010; 56:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/44\">",
"      Finelli PF, DiMario FJ Jr. Hemorrhagic infarction in white matter following acute carbon monoxide poisoning. Neurology 2004; 63:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/45\">",
"      Zagami AS, Lethlean AK, Mellick R. Delayed neurological deterioration following carbon monoxide poisoning: MRI findings. J Neurol 1993; 240:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/46\">",
"      Teksam M, Casey SO, Michel E, et al. Diffusion-weighted MR imaging findings in carbon monoxide poisoning. Neuroradiology 2002; 44:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/47\">",
"      Kim JH, Chang KH, Song IC, et al. Delayed encephalopathy of acute carbon monoxide intoxication: diffusivity of cerebral white matter lesions. AJNR Am J Neuroradiol 2003; 24:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/48\">",
"      Chu K, Jung KH, Kim HJ, et al. Diffusion-weighted MRI and 99mTc-HMPAO SPECT in delayed relapsing type of carbon monoxide poisoning: evidence of delayed cytotoxic edema. Eur Neurol 2004; 51:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/49\">",
"      Hampson NB, Scott KL, Zmaeff JL. Carboxyhemoglobin measurement by hospitals: implications for the diagnosis of carbon monoxide poisoning. J Emerg Med 2006; 31:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/50\">",
"      Hampson NB, Dunford RG, Kramer CC, Norkool DM. Selection criteria utilized for hyperbaric oxygen treatment of carbon monoxide poisoning. J Emerg Med 1995; 13:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/51\">",
"      Leach RM, Rees PJ, Wilmshurst P. Hyperbaric oxygen therapy. BMJ 1998; 317:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/52\">",
"      Ziser A, Shupak A, Halpern P, et al. Delayed hyperbaric oxygen treatment for acute carbon monoxide poisoning. Br Med J (Clin Res Ed) 1984; 289:960.",
"     </a>",
"    </li>",
"    <li>",
"     Goulon M, Barois, Rapin M, et al. Carbon monoxide poisoning and acute anoxia due to breathing coal gas and hydrocarbons. J Hyperbar MEd 1986; 1:23. file://archive.rubicon-foundation.org/xmlui/handle/123456789/4302 (Accessed on October 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/54\">",
"      Weaver LK, Hopkins RO, Chan KJ, et al. Hyperbaric oxygen for acute carbon monoxide poisoning. N Engl J Med 2002; 347:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/55\">",
"      Ducass&eacute; JL, Celsis P, Marc-Vergnes JP. Non-comatose patients with acute carbon monoxide poisoning: hyperbaric or normobaric oxygenation? Undersea Hyperb Med 1995; 22:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/56\">",
"      Scheinkestel CD, Bailey M, Myles PS, et al. Hyperbaric or normobaric oxygen for acute carbon monoxide poisoning: a randomised controlled clinical trial. Med J Aust 1999; 170:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/57\">",
"      Raphael JC, Elkharrat D, Jars-Guincestre MC, et al. Trial of normobaric and hyperbaric oxygen for acute carbon monoxide intoxication. Lancet 1989; 2:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/58\">",
"      Juurlink DN, Buckley NA, Stanbrook MB, et al. Hyperbaric oxygen for carbon monoxide poisoning. Cochrane Database Syst Rev 2005; :CD002041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/59\">",
"      Annane D, Chadda K, Gajdos P, et al. Hyperbaric oxygen therapy for acute domestic carbon monoxide poisoning: two randomized controlled trials. Intensive Care Med 2011; 37:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/60\">",
"      Buckley NA, Juurlink DN, Isbister G, et al. Hyperbaric oxygen for carbon monoxide poisoning. Cochrane Database Syst Rev 2011; :CD002041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/61\">",
"      Koren G, Sharav T, Pastuszak A, et al. A multicenter, prospective study of fetal outcome following accidental carbon monoxide poisoning in pregnancy. Reprod Toxicol 1991; 5:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/62\">",
"      Elkharrat D, Raphael JC, Korach JM, et al. Acute carbon monoxide intoxication and hyperbaric oxygen in pregnancy. Intensive Care Med 1991; 17:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/63\">",
"      Van Hoesen KB, Camporesi EM, Moon RE, et al. Should hyperbaric oxygen be used to treat the pregnant patient for acute carbon monoxide poisoning? A case report and literature review. JAMA 1989; 261:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/64\">",
"      Towers CV, Corcoran VA. Influence of carbon monoxide poisoning on the fetal heart monitor tracing: a report of 3 cases. J Reprod Med 2009; 54:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/65\">",
"      Fisher JA, Rucker J, Sommer LZ, et al. Isocapnic hyperpnea accelerates carbon monoxide elimination. Am J Respir Crit Care Med 1999; 159:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/66\">",
"      Takeuchi A, Vesely A, Rucker J, et al. A simple \"new\" method to accelerate clearance of carbon monoxide. Am J Respir Crit Care Med 2000; 161:1816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/67\">",
"      Rudge FW. Carbon monoxide poisoning in infants: treatment with hyperbaric oxygen. South Med J 1993; 86:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/68\">",
"      Meert KL, Heidemann SM, Sarnaik AP. Outcome of children with carbon monoxide poisoning treated with normobaric oxygen. J Trauma 1998; 44:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/69\">",
"      Kim JK, Coe CJ. Clinical study on carbon monoxide intoxication in children. Yonsei Med J 1987; 28:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/70\">",
"      Cho CH, Chiu NC, Ho CS, Peng CC. Carbon monoxide poisoning in children. Pediatr Neonatol 2008; 49:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10345/abstract/71\">",
"      Waisman D, Shupak A, Weisz G, Melamed Y. Hyperbaric oxygen therapy in the pediatric patient: the experience of the Israel Naval Medical Institute. Pediatrics 1998; 102:E53.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 322 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-2.133.93.82-3DA446CC7F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_6_10345=[""].join("\n");
var outline_f10_6_10345=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      KINETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Symptoms and signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Myocardial injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Delayed neuropsychiatric syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Initial treament and disposition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Hyperbaric oxygen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5571168\">",
"      Hyperbaric oxygen and delayed neuropsychiatric syndrome (DNS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      HBO during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Isocapnic hyperpnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PEDIATRIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32783068\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13112121\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/322\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/322|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?30/19/31038\" title=\"algorithm 1\">",
"      NBO versus HBO algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/322|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/34/28207\" title=\"figure 1\">",
"      Effect of carbon monoxide on oxygen delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/38/32365\" title=\"figure 2\">",
"      Effect of carboxyhemoglobin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/322|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/41/39580\" title=\"table 1\">",
"      Carbon monoxide poisoning - Rapid overview",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/18/7466?source=related_link\">",
"      Cyanide poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5448?source=related_link\">",
"      Hyperbaric oxygen therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19337?source=related_link\">",
"      Hypoxic-ischemic brain injury: Evaluation and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/13/14553?source=related_link\">",
"      Overview of occupational and environmental health",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31430?source=related_link\">",
"      Oxygen delivery and consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/44/17089?source=related_link\">",
"      Patient information: Carbon monoxide (CO) poisoning (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9736?source=related_link\">",
"      Pulse oximetry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22790?source=related_link\">",
"      Smoke inhalation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10377?source=related_link\">",
"      Suicidal ideation and behavior in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_6_10346="Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis";
var content_f10_6_10346=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/6/10346/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/6/10346/contributors\">",
"     Wendy J Pomerantz, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/6/10346/contributors\">",
"     Scott L Weiss, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/6/10346/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/6/10346/contributors\">",
"     Susan B Torrey, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/6/10346/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/6/10346/contributors\">",
"     Adrienne G Randolph, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/6/10346/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/6/10346/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/6/10346/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sepsis is a clinical syndrome that complicates severe infection and is characterized by the systemic inflammatory response syndrome, immune dysregulation, microcirculatory derangements, and end-organ dysfunction. In this syndrome, tissues remote from the original insult display the cardinal signs of inflammation, including vasodilation, increased microvascular permeability, and leukocyte accumulation.",
"   </p>",
"   <p>",
"    Although inflammation is an essential host response, the onset and progression of sepsis center upon a \"dysregulation\" of the normal response, usually with an increase in both proinflammatory and antiinflammatory mediators, initiating a chain of events that leads to widespread tissue injury. Evidence supports a state of acquired immune suppression or immunoparalysis in some patients, which may occur simultaneously with or following the initial proinflammatory response [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10346/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It is this dysregulated host response rather than the primary infectious microorganism that is typically responsible for multiple organ failure and adverse outcomes in sepsis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5449?source=see_link\">",
"     \"Pathophysiology of sepsis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early recognition of sepsis is crucial to ensuring the best outcomes in children and is aided by a working knowledge of the children at particular risk, the common pathogens, and the clinical manifestations. The definition, epidemiology, clinical manifestations, and diagnosis of the systematic inflammatory response syndrome and sepsis in children are discussed here.",
"   </p>",
"   <p>",
"    The rapid recognition, resuscitation, and initial management of pediatric septic shock and the evaluation and management of undifferentiated shock in children are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4634?source=see_link\">",
"       \"Septic shock: Rapid recognition and initial resuscitation in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13354?source=see_link\">",
"       \"Septic shock: Ongoing management after resuscitation in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14104?source=see_link\">",
"       \"Initial evaluation of shock in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=see_link\">",
"       \"Initial management of shock in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitions for sepsis and organ dysfunction for children have been developed by the International Consensus Conference on Pediatric Sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10346/abstract/3\">",
"     3",
"    </a>",
"    ]. These definitions are important for the standardization of observational studies and in the evaluation of therapeutic interventions in clinical trials. They may also be useful in helping clinicians determine the severity of a child's illness and in monitoring clinical progression and response to therapy. However, it should be noted that clinical concern for sepsis should not be limited to pre-defined cut-points for physiologic or laboratory abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10346/abstract/4\">",
"     4",
"    </a>",
"    ]. As an example, in an observational study of 1729 children younger than 18 years of age who were admitted to an intensive care unit, only two-thirds of children treated for severe sepsis or septic shock also met consensus criteria at the time of clinical diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10346/abstract/5\">",
"     5",
"    </a>",
"    ]. Thus, clinical suspicion for sepsis often occurs even though all components of the consensus criteria are",
"    <strong>",
"     not",
"    </strong>",
"    present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1373444\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection is defined as a suspected or proven infection caused by any pathogen. Infections can be proven by positive culture, tissue stain, or polymerase chain reaction test. The definition also includes clinical syndromes associated with a high probability of infection, such as petechiae and purpura in a child with hemodynamic instability, or fever, cough, and hypoxemia in a patient with leukocytosis and pulmonary infiltrates on chest radiograph.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1373453\">",
"    <span class=\"h2\">",
"     Systemic inflammatory response syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The systemic inflammatory response syndrome (SIRS) is a widespread inflammatory response that may or may not be associated with infection. The presence of two or more of the following criteria (one of which must be abnormal temperature or leukocyte count) defines SIRS (",
"    <a class=\"graphic graphic_table graphicRef86087 \" href=\"UTD.htm?26/36/27212\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10346/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Core temperature (measured by rectal, bladder, oral, or central probe) of &gt;38.5&ordm;C or &lt;36&ordm;C",
"     </li>",
"     <li>",
"      Tachycardia, defined as a mean heart rate more than two standard deviations above normal for age, or for children younger than one year of age, bradycardia defined as a mean heart rate &lt;10",
"      <sup>",
"       th",
"      </sup>",
"      percentile for age",
"     </li>",
"     <li>",
"      Mean respiratory rate more than two standard deviations above normal for age or mechanical ventilation for an acute pulmonary process",
"     </li>",
"     <li>",
"      Leukocyte count elevated or depressed for age, or &gt;10 percent immature neutrophils",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61669963\">",
"    <span class=\"h3\">",
"     Age groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;The consensus panel used age-related physiologic and laboratory values to modify definitions that had been developed for adult patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10346/abstract/6\">",
"     6",
"    </a>",
"    ]. Six age groups for age-specific vital signs (heart rate, respiratory rate, and blood pressure) and laboratory variables (leukocyte count) are identified (",
"    <a class=\"graphic graphic_table graphicRef86087 \" href=\"UTD.htm?26/36/27212\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Newborn: 0 days to 1 week",
"     </li>",
"     <li>",
"      Neonate: 1 week to 1 month",
"     </li>",
"     <li>",
"      Infant: 1 month to 1 year",
"     </li>",
"     <li>",
"      Toddler and preschool: &gt;1 to 5 years",
"     </li>",
"     <li>",
"      School age child: &gt;5 to 12 years",
"     </li>",
"     <li>",
"      Adolescent and young adult: &gt;12 to &lt;18 years",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1373466\">",
"    <span class=\"h2\">",
"     Sepsis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The systemic inflammatory response syndrome in the presence of suspected or proven infection constitutes sepsis. Several definitions further describe sepsis in terms of severity and response to therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61670172\">",
"    <span class=\"h3\">",
"     Severity",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Severe sepsis",
"      </strong>",
"      &ndash; Sepsis is considered severe when it is associated with cardiovascular dysfunction, acute respiratory distress syndrome (ARDS), or dysfunction in two or more other organ systems as defined in the section on multiple organ failure below. The diagnostic criteria for ARDS are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link&amp;anchor=H10171195#H10171195\">",
"       \"Acute respiratory distress syndrome: Clinical features and diagnosis\", section on 'Diagnostic criteria'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Septic shock",
"      </strong>",
"      &ndash; Septic shock refers to sepsis with cardiovascular dysfunction (as described in the section on multiple organ failure below) that persists despite the administration of &ge;40",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of isotonic fluid in one hour [",
"      <a class=\"abstract\" href=\"UTD.htm?10/6/10346/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Refractory septic shock",
"      </strong>",
"      &ndash; There are two types of refractory septic shock: fluid-refractory septic shock exists when cardiovascular dysfunction persists despite at least 60",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of fluid resuscitation; and catecholamine-resistant septic shock exists when shock persists despite therapy with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/54/13157?source=see_link\">",
"       dopamine",
"      </a>",
"      &ge;10",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per min",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      direct-acting catecholamines (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/19/37168?source=see_link\">",
"       epinephrine",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/25/1429?source=see_link\">",
"       norepinephrine",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/6/10346/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Multiple organ failure",
"      </strong>",
"      &ndash; Reliably identifying and quantifying organ dysfunction is useful for tracking clinical changes and the response to therapy in children with septic shock. The International Consensus on Pediatric Sepsis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/6/10346/abstract/3\">",
"       3",
"      </a>",
"      ] developed criteria for organ dysfunction based upon several scoring systems [",
"      <a class=\"abstract\" href=\"UTD.htm?10/6/10346/abstract/7-9\">",
"       7-9",
"      </a>",
"      ], taking into account a balance of specificity, sensitivity, and widespread availability of laboratory tests.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Cardiovascular",
"      </strong>",
"      &ndash; Hypotension, or reliance on a vasoactive drug to maintain blood pressure, or two of the following: metabolic acidosis, elevated arterial lactate, oliguria, or prolonged capillary refill",
"     </li>",
"     <li>",
"      <strong>",
"       Respiratory",
"      </strong>",
"      &ndash; Arterial oxygen",
"      <span class=\"nowrap\">",
"       tension/fraction",
"      </span>",
"      of inspired oxygen",
"      <span class=\"nowrap\">",
"       (PaO2/FiO2)",
"      </span>",
"      &lt;300, arterial carbon dioxide tension (PaCO2) &gt;65 torr or 20 mmHg over baseline PaCO2, need for &gt;50 percent FiO2 to maintain oxygen saturation &ge;92 percent, or need for nonelective mechanical ventilation",
"     </li>",
"     <li>",
"      <strong>",
"       Neurologic",
"      </strong>",
"      &ndash; Glasgow coma score &le;11 (",
"      <a class=\"graphic graphic_table graphicRef59662 \" href=\"UTD.htm?2/58/2989\">",
"       table 2",
"      </a>",
"      ), or acute change in mental status",
"     </li>",
"     <li>",
"      <strong>",
"       Hematologic",
"      </strong>",
"      &ndash; Platelet count",
"      <span class=\"nowrap\">",
"       &lt;80,000/microL",
"      </span>",
"      or a decline of 50 percent from highest value recorded over the past three days or disseminated intravascular coagulation (DIC), a consumptive coagulopathy diagnosed by clinical findings of hemorrhage and microthrombi and laboratory abnormalities including thrombocytopenia, prolongation of clotting times (PT and aPTT), and evidence of fibrinolysis (low fibrinogen with elevated fibrin degradation products), which is a common hematologic manifestation in sepsis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8697?source=see_link&amp;anchor=H20#H20\">",
"       \"Disseminated intravascular coagulation in infants and children\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Renal",
"      </strong>",
"      &ndash; Serum creatinine &ge;2 times upper limit of normal for age or twofold increase in baseline creatinine",
"     </li>",
"     <li>",
"      <strong>",
"       Hepatic",
"      </strong>",
"      &ndash; Total bilirubin &ge;4",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (not applicable to newborn) or alanine aminotransferase (ALT) &gt;2 times upper limit of normal for age",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2332152\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among resource-rich countries the best estimates regarding the incidence of severe sepsis come from the United States where approximately 40,000 children develop severe sepsis each year, an estimated annual incidence of 0.6 cases per 1000 population [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10346/abstract/10\">",
"     10",
"    </a>",
"    ]. Respiratory infection and primary bacteremia are found in almost two-thirds of cases of severe sepsis in this population. Since 1960, mortality from pediatric severe sepsis has decreased from 97 percent to approximately 4 to 10 percent in patients with severe sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10346/abstract/10,11\">",
"     10,11",
"    </a>",
"    ] and 13 to 34 percent in patients with septic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10346/abstract/5,10-14\">",
"     5,10-14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13354?source=see_link&amp;anchor=H18270326#H18270326\">",
"     \"Septic shock: Ongoing management after resuscitation in children\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although worldwide estimates for severe sepsis are lacking, infectious diseases account for almost 60 percent of the 7.6 million annual deaths in children younger than five years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10346/abstract/15\">",
"     15",
"    </a>",
"    ]. The majority of these deaths occur in developing countries in Asia and sub-Saharan Africa.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1372491\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among infected children, septic shock, including refractory septic shock or multiple system organ failure, is the most severe form (see",
"    <a class=\"local\" href=\"#H61670172\">",
"     'Severity'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    The following factors have been associated with an increased risk for septic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10346/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age younger than one month",
"     </li>",
"     <li>",
"      Serious injury (eg, major trauma, burns, or penetrating wounds)",
"     </li>",
"     <li>",
"      Chronic debilitating medical condition (eg, static encephalopathy with quadriplegia and frequent aspiration pneumonia, uncorrected congenital heart disease, short gut syndrome)",
"     </li>",
"     <li>",
"      Host immunosuppression (malignancy, human immunodeficiency virus infection, severe malnutrition, congenital immunodeficiency, sickle cell disease and other disease with splenic dysfunction, or immunomodulating medications [eg, chemotherapy])",
"     </li>",
"     <li>",
"      Large surgical incisions",
"     </li>",
"     <li>",
"      In-dwelling vascular catheters or other invasive devices (eg, endotracheal tube, Foley catheter, chest tube)",
"     </li>",
"     <li>",
"      Urinary tract abnormalities with frequent infection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, routine immunization of infants against",
"    <em>",
"     Haemophilus influenzae",
"    </em>",
"    type b and",
"    <em>",
"     Streptococcus pneumoniae",
"    </em>",
"    has resulted in a dramatic decrease in the incidence of invasive disease in young children due to these organisms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=see_link&amp;anchor=H9#H9\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\", section on 'Invasive disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42489?source=see_link&amp;anchor=H7#H7\">",
"     \"Prevention of Haemophilus influenzae infection\", section on 'Efficacy/effectiveness'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PATHOGENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sepsis can be caused by bacterial, viral, fungal, parasitic, and rickettsial infections. Bacteria and viruses are the most frequently identified pathogens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61670371\">",
"    <span class=\"h2\">",
"     Bacteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the frequency of specific pathogenic organisms varies from institution to institution, the most common bacterial pathogens isolated from children with severe sepsis include [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10346/abstract/10,18-23\">",
"     10,18-23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <em>",
"       Staphylococcus aureus",
"      </em>",
"      including methicillin-resistant strains (MRSA)",
"     </li>",
"     <li>",
"      Coagulase-negative Staphylococcus especially in neonates or young infants with in-dwelling vascular catheters",
"     </li>",
"     <li>",
"      <em>",
"       Streptococcus pneumoniae",
"      </em>",
"     </li>",
"     <li>",
"      <em>",
"       Streptococcus pyogenes",
"      </em>",
"     </li>",
"     <li>",
"      Group B streptococcus in the neonate",
"     </li>",
"     <li>",
"      <em>",
"       Pseudomonas aeruginosa",
"      </em>",
"      including carbapenem-resistant strains",
"     </li>",
"     <li>",
"      <em>",
"       Escherichia coli",
"      </em>",
"      , including those with extended spectrum beta-lactamase activity (ESBL)",
"     </li>",
"     <li>",
"      Enterococcus species, including vancomycin-resistant species",
"     </li>",
"     <li>",
"      Klebsiella species, including those with ESBL activity",
"     </li>",
"     <li>",
"      Alpha streptococcus in children with acute myelogenous leukemia with mucositis and neutropenia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although less common, meningococcal infections, especially in unimmunized populations, and the toxic shock syndrome caused by toxin-producing strains of",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    and",
"    <em>",
"     Streptococcus pyogenes",
"    </em>",
"    , remain important additional causes of sepsis in children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37704?source=see_link\">",
"     \"Clinical manifestations of meningococcal infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/52/8010?source=see_link\">",
"     \"Staphylococcal toxic shock syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6616?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome\"",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Factors that alter the prevalence of causative pathogens include age, immunocompromise, and the presence of an in-dwelling vascular catheter:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In young infants three months of age or younger, gram-negative organisms, particularly",
"      <em>",
"       Escherichia coli",
"      </em>",
"      , and Group B streptococcus are most frequently isolated.",
"      <em>",
"       Staphylococcus aureus",
"      </em>",
"      is also a frequent pathogen. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28951?source=see_link&amp;anchor=H12#H12\">",
"       \"Definition and etiology of fever in neonates and infants (less than three months of age)\", section on 'Bacterial pathogens'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with sepsis and febrile neutropenia, both gram-positive (eg, coagulase-negative Staphylococcus,",
"      <em>",
"       Staphylococcus aureus",
"      </em>",
"      ,",
"      <em>",
"       Streptococcus pneumoniae",
"      </em>",
"      ,",
"      <em>",
"       Streptococcus viridians",
"      </em>",
"      ) and gram-negative organisms (eg,",
"      <em>",
"       Pseudomonas aeruginosa",
"      </em>",
"      ,",
"      <em>",
"       Escherichia coli",
"      </em>",
"      , Klebsiella species) are common. Other gram-negative organisms, including Enterobacter, Citrobacter, and Acinetobacter species and",
"      <em>",
"       Stenotrophomonas maltophilia",
"      </em>",
"      , also occur though less frequently. MRSA and multidrug-resistant gram-negative bacteria, such as certain strains of Pseudomonas aeruginosa and ESBL-producing organisms, are frequently isolated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15898?source=see_link&amp;anchor=H4#H4\">",
"       \"Fever in children with chemotherapy-induced neutropenia\", section on 'Etiology of fever'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In hospital-acquired bacterial infections, such as catheter-associated bloodstream infections, coagulase-negative Staphylococcus is the most commonly isolated organism, followed by Gram negative organisms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61670454\">",
"    <span class=\"h2\">",
"     Viruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral pathogens can mimic bacterial sepsis. Etiologies include respiratory viruses (eg, influenza, parainfluenza, adenovirus, respiratory syncytial virus (RSV), and human metapneumovirus) and Dengue virus, a mosquito-borne pathogen that can cause Dengue shock syndrome. While these viruses, especially pandemic H1N1 influenza strain, may cause the sepsis syndrome in isolation, the presence of bacterial co-infections, particularly methicillin-resistant",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    , should be suspected in patients with severe sepsis or septic shock. In immunocompromised patients, EBV, CMV, and adenovirus may also cause sepsis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18985?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical presentation and diagnosis of dengue virus infections\", section on 'Clinical presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37305?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical manifestations and diagnosis of pandemic H1N1 influenza ('swine influenza')\", section on 'Bacterial superinfection'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Herpes simplex virus (HSV), enterovirus and adenovirus infection in neonates and young infants can be indistinguishable from bacterial sepsis. Characteristic vesicular lesions (skin, eye, or mucus membrane) suggesting the diagnosis of herpes simplex may be absent in 30 to 40 percent of infected infants. Most neonates become symptomatic with the first three weeks of life. Nonspecific clinical manifestations include (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/31/35321?source=see_link&amp;anchor=H4#H4\">",
"     \"Neonatal herpes simplex virus infection: Clinical features and diagnosis\", section on 'Clinical manifestations'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Disseminated disease &ndash; Respiratory collapse, liver failure, and disseminated intravascular coagulation",
"     </li>",
"     <li>",
"      Central nervous system disease &ndash; Seizures, lethargy, irritability, and bulging fontanelle",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61670472\">",
"    <span class=\"h2\">",
"     Fungi",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fungal infections, especially candida species, have been reported in 10 percent of pediatric patients with severe sepsis and septic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10346/abstract/10\">",
"     10",
"    </a>",
"    ]. Fungal sepsis is more common in children with certain risk factors including [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10346/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Malignancy or other immunocompromising medical conditions",
"     </li>",
"     <li>",
"      Indwelling vascular catheters",
"     </li>",
"     <li>",
"      Prolonged neutropenia (&gt;4 to 7 days)",
"     </li>",
"     <li>",
"      Recent broad-spectrum antibiotic use",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61670490\">",
"    <span class=\"h2\">",
"     Other pathogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parasitic (eg, malaria) and Rickettsial infections (eg, Rocky Mountain spotted fever) may present with sepsis and should be suspected based upon the local prevalence of disease and travel history. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5543?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations of malaria\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/51/14135?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical manifestations and diagnosis of Rocky Mountain spotted fever\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61670500\">",
"    <span class=\"h2\">",
"     Culture-negative sepsis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Between approximately 30 and 75 percent of children with sepsis have no infectious etiology identified [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10346/abstract/5,17,18\">",
"     5,17,18",
"    </a>",
"    ]. This &ldquo;culture-negative&rdquo; sepsis may indicate host response to bacterial components, such as endotoxin, in the circulatory system or result from antibiotic treatment prior to obtaining bacterial cultures.",
"   </p>",
"   <p>",
"    Alternatively, current diagnostic tests may not be sufficiently sensitive to detect the inciting pathogen in all cases. Newer molecular diagnostic techniques, such as multiplex polymerase chain reaction (PCR), have the potential to improve the rate of organism identification. As an example, in a study comparing multiplex PCR to routine blood culture in 1673 samples obtained from 803 children with suspected sepsis, the rate of positive results was significantly higher with PCR than blood culture (15 versus 10 percent, respectively) with significantly fewer contaminants (2 versus 6 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10346/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with sepsis have significant alterations in vital signs and white blood cell count indicating a systemic inflammatory response (SIRS) in the presence of clinical or laboratory findings of infection. Shock and other organ dysfunction often accompany signs of sepsis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14821477\">",
"    <span class=\"h2\">",
"     Physical findings",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61670563\">",
"    <span class=\"h3\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection is typically suggested by physical findings such as petechiae and purpura in a child with shock, or fever, cough, and hypoxemia in a patient with leukocytosis and pulmonary infiltrates on chest radiograph (",
"    <a class=\"graphic graphic_table graphicRef59769 \" href=\"UTD.htm?2/26/2477\">",
"     table 3",
"    </a>",
"    ). Infections can also be proven by positive culture, tissue stain, or polymerase chain reaction test. However, these results are frequently not available during the initial phase of treatment. Furthermore, in up to 60 percent of patients with sepsis, no pathogen is identified. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Pathogens'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H14817539\">",
"     'Laboratory studies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4570172\">",
"    <span class=\"h3\">",
"     Systemic inflammatory response syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;As defined above, the systemic inflammatory response syndrome (SIRS) is present when a child has an abnormality of temperature (fever or hypothermia) or age-specific abnormality of the white blood cell count",
"    <strong>",
"     and",
"    </strong>",
"    one of the following: tachycardia, bradycardia, respiratory distress, or pulmonary condition requiring mechanical ventilation (",
"    <a class=\"graphic graphic_table graphicRef86087 \" href=\"UTD.htm?26/36/27212\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H1373453\">",
"     'Systemic inflammatory response syndrome'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Among these criteria for SIRS, the presence of fever and tachypnea or fever and abnormal white blood cell count are most common. In an observational study of 92 hospitalized children with SIRS, these two presentations were found in approximately 75 and 50 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10346/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1374189\">",
"    <span class=\"h3\">",
"     Shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence of inadequate tissue perfusion and oxygen delivery with or without hypotension often accompanies sepsis in children. In infants and children, tachycardia is a sensitive, though non-specific, indicator often seen in early stages of shock. Hypotension is a late sign of shock in infants and children who are better able to maintain blood pressure than adults through an increase in heart rate, systemic vascular resistance, and venous tone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42901?source=see_link&amp;anchor=H11#H11\">",
"     \"Physiology and classification of shock in children\", section on 'Common features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other clinical findings of shock vary depending upon whether the patient has distributive (&ldquo;warm&rdquo;) shock or &ldquo;cold&rdquo; shock (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42901?source=see_link&amp;anchor=H11#H11\">",
"     \"Physiology and classification of shock in children\", section on 'Common features'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Distributive (&ldquo;warm&rdquo;) shock",
"      </strong>",
"      &ndash; Distributive shock is characterized by hyperdynamic (or high output) physiology with decreased systemic vascular resistance and elevated cardiac output as manifested by the following findings (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42901?source=see_link&amp;anchor=H9#H9\">",
"       \"Physiology and classification of shock in children\", section on 'Distributive shock'",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Flash capillary refill (&lt;1 second)",
"     </li>",
"     <li>",
"      Bounding pulses",
"     </li>",
"     <li>",
"      Warm, dry extremities",
"     </li>",
"     <li>",
"      Wide pulse pressure (typically greater than 40 mmHg in older children and adults; lower pulse pressures may reflect widening in infants and neonates)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Cold shock",
"      </strong>",
"      &ndash; &ldquo;Cold&rdquo; shock reflects increased systemic vascular resistance and decreased cardiac output as indicated by the following signs (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42901?source=see_link&amp;anchor=H8#H8\">",
"       \"Physiology and classification of shock in children\", section on 'Hypovolemic shock'",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Delayed capillary refill (&gt;2 seconds)",
"     </li>",
"     <li>",
"      Diminished pulses",
"     </li>",
"     <li>",
"      Mottled or cool extremities",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1374196\">",
"    <span class=\"h3\">",
"     Other physical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional clinical findings in infants and children with sepsis may indicate a primary site of infection or arise from organ dysfunction caused by inadequate perfusion and include [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10346/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Toxic or ill appearance",
"     </li>",
"     <li>",
"      Signs of dehydration (eg, dry mucus membranes, sunken eyes, decreased urine output, prolonged capillary refill time, decreased skin turgor, and, in infants, a sunken fontanelle) (",
"      <a class=\"graphic graphic_table graphicRef76198 \" href=\"UTD.htm?13/5/13404\">",
"       table 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Rigors",
"     </li>",
"     <li>",
"      Altered mental status (eg, irritability, anxiety, confusion, lethargy, somnolence)",
"     </li>",
"     <li>",
"      Decreased tone in neonates and infants",
"     </li>",
"     <li>",
"      Seizures",
"     </li>",
"     <li>",
"      Meningismus",
"     </li>",
"     <li>",
"      Respiratory depression or failure",
"     </li>",
"     <li>",
"      Pulmonary rales or decreased breath sounds caused by bronchopneumonia",
"     </li>",
"     <li>",
"      Distended, tender abdomen (eg, perforated viscus or intraabdominal abscess)",
"     </li>",
"     <li>",
"      Costovertebral angle tenderness (eg, pyelonephritis)",
"     </li>",
"     <li>",
"      Macular erythema (toxic shock syndrome) (",
"      <a class=\"graphic graphic_picture graphicRef61786 \" href=\"UTD.htm?22/45/23249\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef82561 \" href=\"UTD.htm?29/4/29761\">",
"       picture 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Skin cellulitis or abscess (",
"      <a class=\"graphic graphic_picture graphicRef53261 \" href=\"UTD.htm?19/51/20287\">",
"       picture 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Peripheral edema caused by capillary leak",
"     </li>",
"     <li>",
"      Petechiae or purpura suggesting either a specific infectious source (eg, meningococcemia, rickettsial infection) or disseminated intravascular coagulopathy (",
"      <a class=\"graphic graphic_picture graphicRef74453 \" href=\"UTD.htm?7/14/7397\">",
"       picture 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef73905 \" href=\"UTD.htm?14/62/15330\">",
"       picture 5",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Multiple nodules which can be seen with disseminated",
"      <em>",
"       S.aureus",
"      </em>",
"      or fungal infections (",
"      <a class=\"graphic graphic_picture graphicRef86621 \" href=\"UTD.htm?42/16/43268\">",
"       picture 6",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14817539\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with suspected sepsis should undergo the following laboratory studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Rapid blood glucose",
"      </strong>",
"      &ndash; Hypoglycemia may accompany the metabolic demands and decreased oral intake associated with sepsis in children, especially in neonates and infants. Stress hyperglycemia may be noted initially and has been most carefully studied in meningococcemia in children [",
"      <a class=\"abstract\" href=\"UTD.htm?10/6/10346/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Arterial blood gas or venous blood gas and pulse oximetry",
"      </strong>",
"      &ndash; Patients with sepsis frequently have inadequate tissue perfusion with lactic acidosis. Hypoxemia from bronchopneumonia or pulmonary edema may also occur.",
"     </li>",
"     <li>",
"      <strong>",
"       Complete blood count with differential (including platelet count)",
"      </strong>",
"      &ndash; Age-specific leukocytosis or leukopenia are a criteria for pediatric SIRS (",
"      <a class=\"graphic graphic_table graphicRef86087 \" href=\"UTD.htm?26/36/27212\">",
"       table 1",
"      </a>",
"      ). In addition, neutrophilia, neutropenia, or thrombocytopenia may indicate acute infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35705?source=see_link&amp;anchor=H19#H19\">",
"       \"Causes of neutrophilia\", section on 'Acute infection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Blood lactate",
"      </strong>",
"      &ndash; Elevation of blood lactate (&gt;3.5",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      obtained by arterial puncture or from an indwelling vascular cannula may help identify the presence and severity of septic shock at presentation. Although evidence is limited in children, reduction in serum or blood lactate levels have been associated with improved survival in adults with shock [",
"      <a class=\"abstract\" href=\"UTD.htm?10/6/10346/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. Preliminary results in an observational study of blood lactate levels in 239 children with SIRS also suggest that venous blood lactate &gt;4",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"      at initial presentation is associated with progression to organ dysfunction at 24 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?10/6/10346/abstract/31\">",
"       31",
"      </a>",
"      ]. Rapid determination of blood lactate may be obtained at the bedside. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=see_link&amp;anchor=H4#H4\">",
"       \"Initial management of shock in children\", section on 'Physiologic indicators and target goals'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Serum electrolytes",
"      </strong>",
"      &ndash; Electrolyte disturbances (eg, hyponatremia, hyperkalemia, hypokalemia, and hypophosphatemia) may accompany disease processes associated with sepsis and septic shock, such as syndrome of inappropriate anti-diuretic hormone secretion, gastroenteritis, and capillary leak.",
"     </li>",
"     <li>",
"      <strong>",
"       Blood urea nitrogen and serum creatinine",
"      </strong>",
"      &ndash; Elevation in blood urea nitrogen may indicate dehydration. Elevation in creatinine may reflect prerenal azotemia. Serum creatinine &ge;2 times upper limit of normal for age or twofold increase in baseline creatinine defines renal dysfunction in the setting of sepsis. (See",
"      <a class=\"local\" href=\"#H1373466\">",
"       'Sepsis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Serum calcium",
"      </strong>",
"      &ndash; Hypocalcemia (ionized calcium &lt;1.1",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      may affect myocardial function and vascular tone and should be corrected if present. If serum calcium is abnormal, serum phosphorus and magnesium should also be measured.",
"     </li>",
"     <li>",
"      <strong>",
"       Serum total bilirubin and alanine aminotransferase",
"      </strong>",
"      &ndash; Total bilirubin &ge;4",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (not applicable to newborn) or alanine aminotransferase (ALT) &gt;2 times upper limit of normal for age indicates liver dysfunction in the setting of sepsis. (See",
"      <a class=\"local\" href=\"#H1373466\">",
"       'Sepsis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Prothrombin time (PT), partial thromboplastin time (aPTT), international normalized ratio (INR)",
"      </strong>",
"      &ndash; Elevation in PT and aPTT or INR suggests disseminated intravascular coagulopathy (DIC).",
"     </li>",
"     <li>",
"      <strong>",
"       Fibrinogen and D-dimer",
"      </strong>",
"      &ndash; Decreased fibrinogen and increased D-dimer support the presence of a consumptive coagulopathy and DIC.",
"     </li>",
"     <li>",
"      <strong>",
"       Blood culture",
"      </strong>",
"      &ndash; Given the high prevalence of bacterial bloodstream infections in children with sepsis, blood cultures should be obtained in all patients, preferably before antibiotics are administered.",
"     </li>",
"     <li>",
"      <strong>",
"       Urinalysis",
"      </strong>",
"      &ndash; The presence of bacteria, nitrites, or pyuria suggests a urinary tract infection.",
"     </li>",
"     <li>",
"      <strong>",
"       Urine culture",
"      </strong>",
"      &ndash; Urinary tract infection is a common source of infection in children with sepsis and catheterized urine cultures should be obtained in all patients, preferably before antibiotic administration.",
"     </li>",
"     <li>",
"      <strong>",
"       Other cultures",
"      </strong>",
"      &ndash; Other cultures (eg, cerebrospinal fluid, wound culture, aspirated fluid from an abscess collection) should be obtained as indicated by clinical findings.",
"     </li>",
"     <li>",
"      <strong>",
"       Diagnostic serologic testing",
"      </strong>",
"      &ndash; For some infections (eg, herpes simplex virus, enterovirus, influenza), other diagnostic testing (eg, viral culture, polymerase chain reaction, rapid immunoassay antigen test, or direct and immunofluorescent antibody staining) may be helpful to establish the source of infection. The user is referred to UpToDate topics on clinical manifestations and diagnosis of the specific infection suspected for guidance on diagnostic testing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Inflammatory biomarkers, such as C-reactive protein and procalcitonin, may be useful in select cases, but routine testing is not currently recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10346/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. For example, procalcitonin and C-reactive protein may be useful in predicting serious bacterial infection infants and young children who present to an emergency department with fever with no apparent source of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10346/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. It may also be useful in predicting bacterial infection in patients with fever and neutropenia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/6/10346/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28074?source=see_link&amp;anchor=H6#H6\">",
"     \"Evaluation and management of fever in the neonate and young infant (less than three months of age)\", section on 'Inflammatory mediators'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14817575\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with tachypnea, rales, wheezing, hypoxemia, or white blood cell count greater than",
"    <span class=\"nowrap\">",
"     20,000/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    warrant a chest radiograph to assess for bronchopneumonia, pulmonary edema, and heart size. Cardiomegaly suggests fluid overload or congenital heart disease.",
"   </p>",
"   <p>",
"    Other imaging may be appropriate depending upon clinical findings. For example, computed tomography of the head may be necessary in the patient with evidence of coagulopathy and altered mental status to evaluate for intracranial hemorrhage; ultrasound or computed tomography of the abdomen may be indicated to evaluate for intra-abdominal abscess.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1374240\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of sepsis is made in children with suspected or proven infection who meet two or more criteria for SIRS (",
"    <a class=\"graphic graphic_table graphicRef86087 \" href=\"UTD.htm?26/36/27212\">",
"     table 1",
"    </a>",
"    ). Pneumonia, bloodstream, skin, or urinary tract infections, and, less commonly, meningitis comprise the most common infections in children with sepsis. (See",
"    <a class=\"local\" href=\"#H1373453\">",
"     'Systemic inflammatory response syndrome'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H13\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Sepsis is primarily a clinical diagnosis. Clinical manifestations typically progress along a continuum of severity from sepsis to severe sepsis (sepsis plus cardiac, respiratory, or dysfunction in two or more other organ systems), septic shock (persistent hemodynamic instability despite initial fluid therapy), and multiple organ failure. (See",
"    <a class=\"local\" href=\"#H61670172\">",
"     'Severity'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    When suspected, the clinician must rapidly respond to signs of hemodynamic instability, organ dysfunction, and administer antibiotics to ensure optimal outcomes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4634?source=see_link&amp;anchor=H19450185#H19450185\">",
"     \"Septic shock: Rapid recognition and initial resuscitation in children\", section on 'Resuscitation'",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1374248\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;All children with findings consistent with sepsis warrant goal-directed therapy and antibiotic administration pending documentation of an infectious etiology. However, several conditions may have similar clinical manifestations, and, once clinical stabilization has occurred, an alternative etiology to sepsis may be evident based upon careful review of clinical findings.",
"   </p>",
"   <p>",
"    In neonates and young infants, alternative diagnoses include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Child abuse (eg, abusive head trauma)",
"     </li>",
"     <li>",
"      Hypoglycemia",
"     </li>",
"     <li>",
"      Environmental hyperthermia",
"     </li>",
"     <li>",
"      Seizures",
"     </li>",
"     <li>",
"      Congenital heart disease, particularly left-sided obstructive lesions (eg, aortic coarctation, hypoplastic left heart syndrome) presenting in patients less than two weeks of age",
"     </li>",
"     <li>",
"      Cardiac arrhythmias (primarily supraventricular tachycardia)",
"     </li>",
"     <li>",
"      Myocarditis or primary cardiomyopathy",
"     </li>",
"     <li>",
"      Inborn errors of metabolism",
"     </li>",
"     <li>",
"      Congenital adrenal hyperplasia",
"     </li>",
"     <li>",
"      Malrotation with volvulus",
"     </li>",
"     <li>",
"      Intussusception",
"     </li>",
"     <li>",
"      Pyloric stenosis",
"     </li>",
"     <li>",
"      Posterior urethral valves",
"     </li>",
"     <li>",
"      Necrotizing enterocolitis",
"     </li>",
"     <li>",
"      Gastroenteritis with dehydration",
"     </li>",
"     <li>",
"      Water intoxication",
"     </li>",
"     <li>",
"      Toxic exposures (eg, methemoglobinemia or carbon monoxide poisoning),",
"     </li>",
"     <li>",
"      Acute bilirubin encephalopathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Detailed history, physical examination, and selected diagnostic studies frequently can differentiate these conditions from sepsis. The approach to the septic-appearing infant is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17018?source=see_link\">",
"     \"Approach to the septic-appearing infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among older children and adolescents the following conditions can cause elevated temperature with tachycardia or hemodynamic instability:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Heat stroke",
"      </strong>",
"      &ndash; The diagnostic criteria for patients with heatstroke are elevated core temperature (&ge;40&ordm;C [104&ordm;F]) and central nervous system (CNS) abnormalities following environmental heat exposure. Other typical clinical manifestations include tachycardia, tachypnea, flushed and warm skin, diaphoresis, and coagulopathy. Exposure to excessive ambient heat is present on history. The height of the fever may exceed 41&deg;C (105.8&deg;C) and an infectious prodrome or source of infection is absent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10234?source=see_link&amp;anchor=H9#H9\">",
"       \"Heat stroke in children\", section on 'Clinical features'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10234?source=see_link&amp;anchor=H8#H8\">",
"       \"Heat stroke in children\", section on 'Differential diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Serotonin syndrome",
"      </strong>",
"      &ndash; Hyperthermia commonly occurs in patients with serotonin syndrome, a potentially life-threatening condition associated with increased serotonergic activity in the central nervous system (CNS). Serotonin syndrome encompasses a spectrum of disease where the intensity of clinical findings is thought to reflect the degree of serotonergic activity. Mental status changes can include anxiety, agitated delirium, restlessness, and disorientation. Patients may startle easily. Autonomic manifestations can include diaphoresis, tachycardia, hyperthermia, hypertension, vomiting, and diarrhea. Neuromuscular hyperactivity can manifest as tremor, muscle rigidity, myoclonus, hyperreflexia, and bilateral Babinski sign. Hyperreflexia and clonus are particularly common; these findings, as well as rigidity, are more often pronounced in the lower extremities.",
"      <br/>",
"      <br/>",
"      The recognition that the patient has been exposed to a serotonergic drug is essential to the diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=see_link\">",
"       \"Serotonin syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Neuroleptic malignant syndrome",
"      </strong>",
"      &ndash; Neuroleptic malignant syndrome (NMS) is an idiosyncratic reaction to antipsychotic agents. In addition to hyperthermia, NMS is also characterized by \"lead pipe\" muscle rigidity, altered mental status, choreoathetosis, tremors, and evidence of autonomic dysfunction, such as diaphoresis, labile blood pressure, and arrhythmias. The history of antipsychotic drug exposure is a key component of the diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=see_link\">",
"       \"Neuroleptic malignant syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Malignant hyperthermia",
"      </strong>",
"      &ndash; Malignant hyperthermia is a rare genetic disorder that manifests following exposure to certain agents, most commonly",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/58/39845?source=see_link\">",
"       succinylcholine",
"      </a>",
"      and halothane. Other potent inhalational anesthetics (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/47/23286?source=see_link\">",
"       sevoflurane",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/44/5830?source=see_link\">",
"       desflurane",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/63/17397?source=see_link\">",
"       isoflurane",
"      </a>",
"      ) can also cause malignant hyperthermia. The onset of malignant hyperthermia is usually within one hour of the administration of general anesthesia, but rarely, may be delayed up to 10 hours after induction. Clinical manifestations include hypercapnia, hyperthermia, tachycardia, masseter muscle rigidity, and rhabdomyolysis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32984?source=see_link\">",
"       \"Malignant hyperthermia: Clinical diagnosis and management of acute crisis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Toxic overdose",
"      </strong>",
"      &ndash; Drug-related causes of hyperthermia, tachycardia, shock, and multiple organ dysfunctions include overdose of cocaine, methamphetamine or related compounds (eg, bath salts), amphetamine, MDMA [ecstasy], salicylates, anticholinergic agents and withdrawal from opioid or benzodiazepine medications. A history of drug exposure, an elevated salicylate level, or a positive toxicology screen for drugs of abuse may be present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23018?source=see_link\">",
"       \"Cocaine: Acute intoxication\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21560?source=see_link\">",
"       \"MDMA (ecstasy) intoxication\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/29/474?source=see_link\">",
"       \"Methamphetamine intoxication\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43319?source=see_link\">",
"       \"Anticholinergic poisoning\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/41/19098?source=see_link\">",
"       \"Salicylate poisoning in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Kawasaki disease",
"      </strong>",
"      &ndash; Kawasaki disease is a clinical syndrome consisting of fever for &ge;5 days and four of five physical findings (bilateral bulbar conjunctival injection, oral mucous membrane changes (eg, injected lips or strawberry tongue), peripheral extremity changes (erythema of palms or soles, edema of hands or feet, and eventual periungual desquamation), rash, or cervical lymphadenopathy. Tachycardia is frequently present and poor peripheral perfusion may occur, especially in infants. However, shock is unusual in patients with Kawasaki disease. Shock may be present in up to 7 percent of children with Kawasaki disease [",
"      <a class=\"abstract\" href=\"UTD.htm?10/6/10346/abstract/38\">",
"       38",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12248?source=see_link&amp;anchor=H2#H2\">",
"       \"Kawasaki disease: Clinical features and diagnosis\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/44/7878?source=see_link\">",
"       Baclofen",
"      </a>",
"      <strong>",
"       withdrawal syndrome",
"      </strong>",
"      &ndash; Baclofen is chemically derived from the natural inhibitory neurotransmitter gamma aminobutyric acid (GABA) and binds to GABA",
"      <sub>",
"       b",
"      </sub>",
"      receptors that inhibit neuronal excitation in the spinal cord [",
"      <a class=\"abstract\" href=\"UTD.htm?10/6/10346/abstract/39\">",
"       39",
"      </a>",
"      ]. Intrathecal baclofen has become an established therapy for spasticity in children with cerebral palsy. The medication is delivered by a programmable pump that is implanted in the subcutaneous layer of the abdomen. Baclofen withdrawal may occur if the pump fails, the delivery catheter becomes occluded, the medication runs out, or the amount of baclofen in the pump reservoir falls below 2 mL [",
"      <a class=\"abstract\" href=\"UTD.htm?10/6/10346/abstract/39,40\">",
"       39,40",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      One to three days after abrupt withdrawal of baclofen, the patient can develop marked spasticity, muscle rigidity, seizures, hyperthermia, hypertension, pruritis and, in advanced cases, rhabdomyolysis with multiple system organ failure and disseminated intravascular coagulopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?10/6/10346/abstract/39,41,42\">",
"       39,41,42",
"      </a>",
"      ]. These manifestations may be confused with other diseases including sepsis, serotonin syndrome, or neuroleptic malignant syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?10/6/10346/abstract/39,42,43\">",
"       39,42,43",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The diagnosis of baclofen withdrawal is made when evaluation of the pump identifies an empty or low drug reservoir or an unexpectedly full reservoir indicating tubing failure [",
"      <a class=\"abstract\" href=\"UTD.htm?10/6/10346/abstract/39,42\">",
"       39,42",
"      </a>",
"      ]. Resumption of intrathecal baclofen delivery is the definitive treatment. Benzodiazepine administration (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/22/25959?source=see_link\">",
"       lorazepam",
"      </a>",
"      ) may temporarily control spasticity and seizures until intrathecal baclofen can be reestablished. High-dose oral baclofen may also be attempted but is frequently not effective.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2745623\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The systemic inflammatory response syndrome (SIRS) is present when a child has an abnormality of temperature (fever or hypothermia) or age-specific abnormality of the white blood cell count",
"      <strong>",
"       and",
"      </strong>",
"      one of the following: tachycardia, bradycardia, respiratory distress, or pulmonary condition requiring mechanical ventilation (",
"      <a class=\"graphic graphic_table graphicRef86087 \" href=\"UTD.htm?26/36/27212\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1373453\">",
"       'Systemic inflammatory response syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The systemic inflammatory response syndrome in the presence of suspected or proven infection constitutes sepsis. Clinical manifestations typically progress along a continuum of severity from sepsis to severe sepsis, septic shock, and multiple organ failure. (See",
"      <a class=\"local\" href=\"#H1373466\">",
"       'Sepsis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H61670172\">",
"       'Severity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infection is typically suggested by physical findings such as petechiae and purpura in a child with shock, or fever, cough, and hypoxemia in a patient with leukocytosis and pulmonary infiltrates on chest radiograph (",
"      <a class=\"graphic graphic_table graphicRef59769 \" href=\"UTD.htm?2/26/2477\">",
"       table 3",
"      </a>",
"      ). Infections can also be proven by positive culture, tissue stain, or polymerase chain reaction test. However, these results are frequently not available during the initial phase of treatment. Furthermore, in up to 60 percent of patients with sepsis, no pathogen is identified. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Pathogens'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14817539\">",
"       'Laboratory studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bacterial, viral, fungal, parasitic, and rickettsial infections can all cause sepsis. Common bacteria that cause severe sepsis include",
"      <em>",
"       Staphylococcus aureus",
"      </em>",
"      ,",
"      <em>",
"       Streptococcus pneumoniae",
"      </em>",
"      , and gram-negative organisms. Viral pathogens can mimic bacterial sepsis, especially herpes simplex virus infection and enterovirus in neonates (&le;28 days of age). However, the presence of bacterial co-infections, particularly",
"      <em>",
"       Staphylococcus aureus",
"      </em>",
"      , should be suspected in patients with severe sepsis or septic shock. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Pathogens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical findings of septic shock may include fever, a toxic or ill appearance, edema (as the result of capillary leak), respiratory distress, altered mental status, and inadequate tissue perfusion. Patients may have &ldquo;warm shock&rdquo; with decreased systemic vascular resistance (SVR, bounding pulses and normal or flash capillary refill) or &ldquo;cold shock&rdquo; with poor peripheral perfusion due to increased SVR (decreased capillary refill, decreased peripheral pulses as compared with central pulses). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All children with findings consistent with sepsis warrant timely antibiotic administration and prompt initiation of goal-directed therapy pending documentation of an infectious etiology. However, several conditions may have similar clinical manifestations, and, once clinical stabilization has occurred, an alternative etiology to sepsis may be evident based upon careful review of clinical findings. (See",
"      <a class=\"local\" href=\"#H1374248\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of septic shock is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4634?source=see_link\">",
"       \"Septic shock: Rapid recognition and initial resuscitation in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13354?source=see_link\">",
"       \"Septic shock: Ongoing management after resuscitation in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10346/abstract/1\">",
"      Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10346/abstract/2\">",
"      Hall MW, Knatz NL, Vetterly C, et al. Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome. Intensive Care Med 2011; 37:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10346/abstract/3\">",
"      Goldstein B, Giroir B, Randolph A, International Consensus Conference on Pediatric Sepsis. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 2005; 6:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10346/abstract/4\">",
"      Brierley J, Carcillo JA, Choong K, et al. Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine. Crit Care Med 2009; 37:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10346/abstract/5\">",
"      Weiss SL, Parker B, Bullock ME, et al. Defining pediatric sepsis by different criteria: discrepancies in populations and implications for clinical practice. Pediatr Crit Care Med 2012; 13:e219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10346/abstract/6\">",
"      Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2003; 29:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10346/abstract/7\">",
"      Wilkinson JD, Pollack MM, Glass NL, et al. Mortality associated with multiple organ system failure and sepsis in pediatric intensive care unit. J Pediatr 1987; 111:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10346/abstract/8\">",
"      Leteurtre S, Martinot A, Duhamel A, et al. Validation of the paediatric logistic organ dysfunction (PELOD) score: prospective, observational, multicentre study. Lancet 2003; 362:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10346/abstract/9\">",
"      Graciano AL, Balko JA, Rahn DS, et al. The Pediatric Multiple Organ Dysfunction Score (P-MODS): development and validation of an objective scale to measure the severity of multiple organ dysfunction in critically ill children. Crit Care Med 2005; 33:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10346/abstract/10\">",
"      Watson RS, Carcillo JA, Linde-Zwirble WT, et al. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med 2003; 167:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10346/abstract/11\">",
"      Odetola FO, Gebremariam A, Freed GL. Patient and hospital correlates of clinical outcomes and resource utilization in severe pediatric sepsis. Pediatrics 2007; 119:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10346/abstract/12\">",
"      Kutko MC, Calarco MP, Flaherty MB, et al. Mortality rates in pediatric septic shock with and without multiple organ system failure. Pediatr Crit Care Med 2003; 4:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10346/abstract/13\">",
"      Jaramillo-Bustamante JC, Mar&iacute;n-Agudelo A, Fern&aacute;ndez-Laverde M, Bare&ntilde;o-Silva J. Epidemiology of sepsis in pediatric intensive care units: first Colombian multicenter study. Pediatr Crit Care Med 2012; 13:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10346/abstract/14\">",
"      Han YY, Carcillo JA, Dragotta MA, et al. Early reversal of pediatric-neonatal septic shock by community physicians is associated with improved outcome. Pediatrics 2003; 112:793.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Global health observatory. file://www.who.int/gho/child_health/en/index.html (Accessed on August 08, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10346/abstract/16\">",
"      Butt W. Septic shock. Pediatr Clin North Am 2001; 48:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10346/abstract/17\">",
"      Gaines NN, Patel B, Williams EA, Cruz AT. Etiologies of septic shock in a pediatric emergency department population. Pediatr Infect Dis J 2012; 31:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10346/abstract/18\">",
"      Nadel S, Goldstein B, Williams MD, et al. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 2007; 369:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10346/abstract/19\">",
"      Hussain FM, Boyle-Vavra S, Bethel CD, Daum RS. Current trends in community-acquired methicillin-resistant Staphylococcus aureus at a tertiary care pediatric facility. Pediatr Infect Dis J 2000; 19:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10346/abstract/20\">",
"      Yogaraj JS, Elward AM, Fraser VJ. Rate, risk factors, and outcomes of nosocomial primary bloodstream infection in pediatric intensive care unit patients. Pediatrics 2002; 110:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10346/abstract/21\">",
"      Lee CY, Chen PY, Huang FL, Lin CF. Microbiologic spectrum and susceptibility pattern of clinical isolates from the pediatric intensive care unit in a single medical center - 6 years' experience. J Microbiol Immunol Infect 2009; 42:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10346/abstract/22\">",
"      Jones RN. Resistance patterns among nosocomial pathogens: trends over the past few years. Chest 2001; 119:397S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10346/abstract/23\">",
"      National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10346/abstract/24\">",
"      Zaoutis TE, Prasad PA, Localio AR, et al. Risk factors and predictors for candidemia in pediatric intensive care unit patients: implications for prevention. Clin Infect Dis 2010; 51:e38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10346/abstract/25\">",
"      Lucignano B, Ranno S, Liesenfeld O, et al. Multiplex PCR allows rapid and accurate diagnosis of bloodstream infections in newborns and children with suspected sepsis. J Clin Microbiol 2011; 49:2252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10346/abstract/26\">",
"      Pavare J, Grope I, Gardovska D. Prevalence of systemic inflammatory response syndrome (SIRS) in hospitalized children: a point prevalence study. BMC Pediatr 2009; 9:25.",
"     </a>",
"    </li>",
"    <li>",
"     Dhanani S, Cox PN. Infectious syndromes in the pediatric intensive care unit. In: Fuhrman &amp; Zimmerman's Pediatric Critical Care, 4th edition, Fuhrman BP, Zimmerman JJ.  (Eds), Elsevier Saunders, Philadelphia 2011. p.1336.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10346/abstract/28\">",
"      van Waardenburg DA, Jansen TC, Vos GD, Buurman WA. Hyperglycemia in children with meningococcal sepsis and septic shock: the relation between plasma levels of insulin and inflammatory mediators. J Clin Endocrinol Metab 2006; 91:3916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10346/abstract/29\">",
"      Jansen TC, van Bommel J, Mulder PG, et al. The prognostic value of blood lactate levels relative to that of vital signs in the pre-hospital setting: a pilot study. Crit Care 2008; 12:R160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10346/abstract/30\">",
"      Levy B, Perez P, Gibot S, Gerard A. Increased muscle-to-serum lactate gradient predicts progression towards septic shock in septic patients. Intensive Care Med 2010; 36:1703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10346/abstract/31\">",
"      Scott HF, Donoghue AJ, Gaieski DF, et al. The utility of early lactate testing in undifferentiated pediatric systemic inflammatory response syndrome. Acad Emerg Med 2012; 19:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10346/abstract/32\">",
"      Marshall JC, Reinhart K, International Sepsis Forum. Biomarkers of sepsis. Crit Care Med 2009; 37:2290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10346/abstract/33\">",
"      Kaplan JM, Wong HR. Biomarker discovery and development in pediatric critical care medicine. Pediatr Crit Care Med 2011; 12:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10346/abstract/34\">",
"      Luaces-Cubells C, Mintegi S, Garc&iacute;a-Garc&iacute;a JJ, et al. Procalcitonin to detect invasive bacterial infection in non-toxic-appearing infants with fever without apparent source in the emergency department. Pediatr Infect Dis J 2012; 31:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10346/abstract/35\">",
"      Maniaci V, Dauber A, Weiss S, et al. Procalcitonin in young febrile infants for the detection of serious bacterial infections. Pediatrics 2008; 122:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10346/abstract/36\">",
"      Hatzistilianou M, Rekliti A, Athanassiadou F, Catriu D. Procalcitonin as an early marker of bacterial infection in neutropenic febrile children with acute lymphoblastic leukemia. Inflamm Res 2010; 59:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10346/abstract/37\">",
"      Juutilainen A, H&auml;m&auml;l&auml;inen S, Pulkki K, et al. Biomarkers for bacteremia and severe sepsis in hematological patients with neutropenic fever: multivariate logistic regression analysis and factor analysis. Leuk Lymphoma 2011; 52:2349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10346/abstract/38\">",
"      Kanegaye JT, Wilder MS, Molkara D, et al. Recognition of a Kawasaki disease shock syndrome. Pediatrics 2009; 123:e783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10346/abstract/39\">",
"      Salazar ML, Eiland LS. Intrathecal baclofen withdrawal resembling serotonin syndrome in an adolescent boy with cerebral palsy. Pediatr Emerg Care 2008; 24:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10346/abstract/40\">",
"      Rigoli G, Terrini G, Cordioli Z. Intrathecal baclofen withdrawal syndrome caused by low residual volume in the pump reservoir: a report of 2 cases. Arch Phys Med Rehabil 2004; 85:2064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10346/abstract/41\">",
"      Alden TD, Lytle RA, Park TS, et al. Intrathecal baclofen withdrawal: a case report and review of the literature. Childs Nerv Syst 2002; 18:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10346/abstract/42\">",
"      Zuckerbraun NS, Ferson SS, Albright AL, Vogeley E. Intrathecal baclofen withdrawal: emergent recognition and management. Pediatr Emerg Care 2004; 20:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/6/10346/abstract/43\">",
"      Kao LW, Amin Y, Kirk MA, Turner MS. Intrathecal baclofen withdrawal mimicking sepsis. J Emerg Med 2003; 24:423.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6395 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-59FAC149C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_6_10346=[""].join("\n");
var outline_f10_6_10346=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2745623\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1373444\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1373453\">",
"      Systemic inflammatory response syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H61669963\">",
"      - Age groups",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1373466\">",
"      Sepsis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H61670172\">",
"      - Severity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2332152\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1372491\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PATHOGENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H61670371\">",
"      Bacteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H61670454\">",
"      Viruses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H61670472\">",
"      Fungi",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H61670490\">",
"      Other pathogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H61670500\">",
"      Culture-negative sepsis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14821477\">",
"      Physical findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H61670563\">",
"      - Infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4570172\">",
"      - Systemic inflammatory response syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1374189\">",
"      - Shock",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1374196\">",
"      - Other physical findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14817539\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14817575\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1374240\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1374248\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2745623\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6395\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6395|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/45/23249\" title=\"picture 1\">",
"      Toxic shock syndrome - macular erythema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/4/29761\" title=\"picture 2\">",
"      Macular erythema in toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/51/20287\" title=\"picture 3\">",
"      Skin abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/14/7397\" title=\"picture 4\">",
"      Disseminated intravascular coagulation acral purpura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/62/15330\" title=\"picture 5\">",
"      Petechiae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/16/43268\" title=\"picture 6\">",
"      Skin nodule associated with Staphyloccoccus aureus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6395|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/36/27212\" title=\"table 1\">",
"      Pediatric systemic inflammatory response syndrome criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/58/2989\" title=\"table 2\">",
"      Glasgow and pediatric coma scales",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/26/2477\" title=\"table 3\">",
"      Evaluation of sources of sepsis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/5/13404\" title=\"table 4\">",
"      Pediatric signs of dehydration",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=related_link\">",
"      Acute respiratory distress syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43319?source=related_link\">",
"      Anticholinergic poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17018?source=related_link\">",
"      Approach to the septic-appearing infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35705?source=related_link\">",
"      Causes of neutrophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/51/14135?source=related_link\">",
"      Clinical manifestations and diagnosis of Rocky Mountain spotted fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37305?source=related_link\">",
"      Clinical manifestations and diagnosis of pandemic H1N1 influenza ('swine influenza')",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5543?source=related_link\">",
"      Clinical manifestations of malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37704?source=related_link\">",
"      Clinical manifestations of meningococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18985?source=related_link\">",
"      Clinical presentation and diagnosis of dengue virus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23018?source=related_link\">",
"      Cocaine: Acute intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28951?source=related_link\">",
"      Definition and etiology of fever in neonates and infants (less than three months of age)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8697?source=related_link\">",
"      Disseminated intravascular coagulation in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6616?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28074?source=related_link\">",
"      Evaluation and management of fever in the neonate and young infant (less than three months of age)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15898?source=related_link\">",
"      Fever in children with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10234?source=related_link\">",
"      Heat stroke in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14104?source=related_link\">",
"      Initial evaluation of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=related_link\">",
"      Initial management of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12248?source=related_link\">",
"      Kawasaki disease: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21560?source=related_link\">",
"      MDMA (ecstasy) intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32984?source=related_link\">",
"      Malignant hyperthermia: Clinical diagnosis and management of acute crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/29/474?source=related_link\">",
"      Methamphetamine intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/31/35321?source=related_link\">",
"      Neonatal herpes simplex virus infection: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=related_link\">",
"      Neuroleptic malignant syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5449?source=related_link\">",
"      Pathophysiology of sepsis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42901?source=related_link\">",
"      Physiology and classification of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42489?source=related_link\">",
"      Prevention of Haemophilus influenzae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/41/19098?source=related_link\">",
"      Salicylate poisoning in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13354?source=related_link\">",
"      Septic shock: Ongoing management after resuscitation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4634?source=related_link\">",
"      Septic shock: Rapid recognition and initial resuscitation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=related_link\">",
"      Serotonin syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/52/8010?source=related_link\">",
"      Staphylococcal toxic shock syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_6_10347="Special semen analysis";
var content_f10_6_10347=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F51745&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F51745&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Specialized tests for semen analysis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Sperm autoantibodies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Semen biochemistry (semen fructose)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Semen culture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sperm-cervical mucus interaction tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Sperm function tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Computer-aided sperm analysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Acrosome reaction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Zona free hamster oocyte penetration test",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Human zona pellucida binding test",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sperm reactive oxygen species generation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sperm chromatin/DNA assays",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_6_10347=[""].join("\n");
var outline_f10_6_10347=null;
var title_f10_6_10348="PKU diet guidelines";
var content_f10_6_10348=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71966&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71966&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Phenylketonuria dietary guidelines",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Green group:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       The foods in this group can be eaten without calculation of phenylalanine content:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Fruits: Apples, pears, watermelon, cherries",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Vegetables: Green lettuce, cucumbers, tomatoes, carrots",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Dairy: Butter, margarine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Grains: Low-protein flour, low-protein bread, low-protein noodles, low-protein crackers, low-protein rice",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Beverages: Lemonade, soft drinks (without aspartame), tea, mineral water",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Yellow group:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       The foods in this group contain medium levels of phenylalanine, and phenyalanine intake should be calculated:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Fruits: Bananas",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Vegetables: Potatoes, french fries, potato chips",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Dairy: PKU milk, creme fraiche, ice cream",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Beverages: Concentrated fruit juices",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Red group:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       The foods in this group contain high levels of phenylalanine and should not be eaten by patients with phenylketonuria:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Meat (sausage), fish, eggs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Nuts, soybeans, lentils, peas, beans (and products made from these foods)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Dairy: Milk, cheese (including soft, white, fresh cheese, also known as quark or pot cheese)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Grains: Porridge, m&uuml;esli, regular bread, regular noodles",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Other: Chocolate",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Olaf A Bodamer, MD, FACMG, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_6_10348=[""].join("\n");
var outline_f10_6_10348=null;
var title_f10_6_10349="Medications for malabsorption";
var content_f10_6_10349=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F51385&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F51385&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Medications used in malabsorption and maldigestion (adult)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Medication/dosage",
"      </td>",
"      <td class=\"subtitle1\">",
"       Comment",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"2\">",
"       Antidiarrheal agents",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Loperamide 2-4 mg as needed, not to exceed 12 mg/day",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Diphenoxylate with atropine (Lomotil&reg;) 1-2 tabs after loose stool, not to exceed 8 per day",
"      </td>",
"      <td class=\"sublist_other\">",
"       1 tab = 2.5 mg diphenoxylate component",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Deodorized opium tincture 10 percent (10 mg per mL) 0.3 to 0.6 mL three times daily",
"      </td>",
"      <td class=\"sublist_other\">",
"       Note: Highly concentrated. Contains 25 times more morphine than paregoric. Abrupt discontinuation may cause withdrawal symptoms.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"2\">",
"       Bile acid binding resins",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Cholestyramine 4 g three times daily",
"      </td>",
"      <td class=\"sublist_other\">",
"       Administer &ge;1 hour before or &gt;4 hours after other drugs to prevent decreased absorption of other drug(s)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Colestipol granules 5-10 g three times daily",
"      </td>",
"      <td class=\"sublist_other\">",
"       Administer &ge;1 hour before or &gt;4 hours after other drugs to prevent decreased absorption of other drug(s)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Pancreatic enzymes*",
"      </td>",
"      <td class=\"sublist_other_start\">",
"       General: Approximately 30,000 units (lipase component) with each meal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Pancrelipase delayed-release capsules (Creon minimicrospheres)",
"      </td>",
"      <td class=\"sublist_other\">",
"       Enteric-coated micro pellets may be sprinkled on soft acidic foods",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Pancrelipase tablets and powder (Viokase, others) 1 g (equivalent to 20,000 units lipase component) with meals",
"      </td>",
"      <td class=\"sublist_other\">",
"       Effect improved if given with acid-suppressing drugs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"2\">",
"       Vitamins and minerals&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Vitamin A 40,000-50,000 units twice daily during acute repletion",
"      </td>",
"      <td class=\"sublist_other\">",
"       Maintenance: 8000-20,000 units/day (Dosage &ge;15,000 units can be teratogenic)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Vitamin D3 (cholecalciferol) 30,000-50,000 units/day",
"      </td>",
"      <td class=\"sublist_other\">",
"       Monitor serum calcium",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Vitamin K 2.5-12.5 mg daily",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Folic acid 5 mg/day during repletion",
"      </td>",
"      <td class=\"sublist_other\">",
"       Maintenance: 1 mg/day",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Vitamin B12 (cyanocobalamin) 1 mg subcutaneously (should be repeated x three over first week of repletion)",
"      </td>",
"      <td class=\"sublist_other\">",
"       Maintenance: 100 mcg q 1-2 months",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Calcium carbonate 500 mg (elemental calcium) twice daily",
"      </td>",
"      <td>",
"       Monitor serum calcium",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Magnesium gluconate 1-4 g (54-216 mg elemental magnesium) four times daily",
"      </td>",
"      <td>",
"       Often produces diarrhea",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ferrous sulfate&Delta; 325 mg (65 mg elemental iron) three times daily",
"      </td>",
"      <td>",
"       Dose reduce if gastrointestinal symptoms occur",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     All dosages are oral, if not otherwise stated.",
"     <br>",
"      * Dose titration may be needed.",
"      <br>",
"       &bull; Maintenance doses for fat-soluble vitamins are highly dependent upon the degree of ongoing malabsorption. Blood levels should be checked every one to two years.",
"       <br>",
"        &Delta; Available as a solution. Equivalent dosage mixed in 8 ounces orange juice will greatly enhance absorptive efficiency due to vitamin C content of juice.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Heimburger DC, Weinsier RL. Gastrointestinal and liver diseases, In: Handbook of Clinical Nutrition, 3rd ed, Heimburger DC, Weinsier RL (Eds), Mosby, St Louis 1997. p.424.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_6_10349=[""].join("\n");
var outline_f10_6_10349=null;
var title_f10_6_10350="Contents: Spinal disease and back pain";
var content_f10_6_10350=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?3/39/3710\">",
"       Rheumatology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Spinal disease and back pain",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Spinal disease and back pain",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Ankylosing spondylitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/23/35194\">",
"           Assessment and treatment of ankylosing spondylitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/9/151\">",
"           Clinical manifestations of ankylosing spondylitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/51/12090\">",
"           Pathogenesis of spondyloarthritis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Low back pain",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/10/18601\">",
"           Approach to the diagnosis and evaluation of low back pain in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/7/14458\">",
"           Clinical manifestations and treatment of osteoporotic thoracolumbar vertebral compression fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/21/12633\">",
"           Diagnostic testing for low back pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/43/6841\">",
"           Exercise-based therapy for low back pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/28/1480\">",
"           Lumbar spinal stenosis: Pathophysiology, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/15/22776\">",
"           Lumbar spinal stenosis: Treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/34/42535\">",
"           Occupational low back pain: Evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/47/14072\">",
"           Occupational low back pain: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/16/41222\">",
"           Spinal manipulation in the treatment of musculoskeletal pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/52/39753\">",
"           Subacute and chronic low back pain: Nonsurgical interventional treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/24/19850\">",
"           Subacute and chronic low back pain: Pharmacologic and noninterventional treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/5/34905\">",
"           Subacute and chronic low back pain: Surgical treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/21/13658\">",
"           Treatment of acute low back pain",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neck pain",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/18/27944\">",
"           Cervical spondylotic myelopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/19/36152\">",
"           Clinical features and diagnosis of cervical radiculopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/24/1418\">",
"           Evaluation of the patient with neck pain and cervical spine disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/47/17144\">",
"           Treatment of cervical radiculopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/36/23113\">",
"           Treatment of neck pain",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/6/35940\">",
"           Coccydynia (coccygodynia)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/16/41222\">",
"           Spinal manipulation in the treatment of musculoskeletal pain",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-F343A8C3F4-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f10_6_10350=[""].join("\n");
var outline_f10_6_10350=null;
var title_f10_6_10351="Listeria";
var content_f10_6_10351=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F70010&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F70010&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Listeria stain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 292px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram stain of blood culture broth containing Listeria.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: McClatchey KD M.D., D.D.S. Clinical Laboratory Medicine, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2002. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_6_10351=[""].join("\n");
var outline_f10_6_10351=null;
